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Abstract
Cell therapies for autoimmune diseases using tolerogenic dendritic cells (tolDC) have been promisingly explored. A major 
stumbling block has been generating stable tolDC, with low risk of converting to mature immunogenic DC (mDC), exacer-
bating disease. mDC induction involves a metabolic shift to lactate production from oxidative phosphorylation (OXPHOS) 
and β-oxidation, the homeostatic energy source for resting DC. Inhibition of glycolysis through the administration of 2-deoxy 
glucose (2-DG) has been shown to prevent autoimmune disease experimentally but is not clinically feasible. We show here 
that treatment of mouse bone marrow-derived tolDC ex vivo with low-dose 2-DG (2.5 mM) (2-DGtolDC) induces a stable 
tolerogenic phenotype demonstrated by their failure to engage lactate production when challenged with mycobacterial antigen 
(Mtb). ~ 15% of 2-DGtolDC express low levels of MHC class II and 30% express CD86, while they are negative for CD40. 
2-DGtolDC also express increased immune checkpoint molecules PDL-1 and SIRP-1α. Antigen-specific T cell proliferation 
is reduced in response to 2-DGtolDC in vitro. Mtb-stimulated 2-DGtolDC do not engage aerobic glycolysis but respond to 
challenge via increased OXPHOS. They also have decreased levels of p65 phosphorylation, with increased phosphoryla-
tion of the non-canonical p100 pathway. A stable tolDC phenotype is associated with sustained SIRP-1α phosphorylation 
and p85-AKT and PI3K signalling inhibition. Further, 2-DGtolDC preferentially secrete IL-10 rather than IL-12 upon 
Mtb-stimulation. Importantly, a single subcutaneous administration of 2-DGtolDC prevented experimental autoimmune 
uveoretinitis (EAU) in vivo. Inhibiting glycolysis of autologous tolDC prior to transfer may be a useful approach to provid-
ing stable tolDC therapy for autoimmune/immune-mediated diseases.
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Introduction
Dendritic cells [1] are a diverse, heterogeneous group of 
specialist immune cells that are the immune system’s pri-
mary professional antigen-presenting cells. Recent studies 
[2, 3] have described the various differentiation pathways 
of bone marrow progenitor DC from the time they enter the 
circulation as immature precursors (pre-DC) to when they 
populate the tissues as tissue-resident DC, and/or migrate to 
secondary lymphoid organs in a CCR7-dependent manner. 
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During steady-state conditions, tissue-resident DC maintain 
immunological homeostasis by presenting self-antigen in the 
absence of co-stimulation. This ensures non-responsiveness 
to self-antigen by inducing T regulatory cells  (TREG) or T 
cell anergy, in an NFκB-dependent mechanism [4], a pro-
cess that is known as peripheral immune tolerance [5]. 
Dendritic cells also function to connect innate and adap-
tive immunity; when antigen presentation is coupled with 
“danger signals” (PAMPs, DAMPs), DC upregulate co-
stimulatory molecules, and both, in conjunction, elicit an 
immune response. This dual function of tolerance induction 
by tolDC, and induction of immune responses by mature 
DC (mDC), makes using tolDC to promote immunological 
tolerance, an attractive prospect. Indeed, several pre-clinical 
studies, and Phase I/II clinical trials, have shown benefits in 
multiple diseases [6–9].
The harvesting and use of autologous tolDC as a thera-
peutic for the treatment of autoimmune disease and graft 
rejection has been explored in numerous studies [10–15]. 
Producing a sufficiently high yield of tolDC from either 
bone marrow (mouse), or circulating (human) precursors, 
via in vitro culture with granulocyte-monocyte colony-stim-
ulating factor (GM-CSF) [16, 17] has been a difficult task 
for researchers. Several additional agents have been used 
to promote differentiation of tolDC, including vitamin D 
and dexamethasone (VitD/dex) [18–23], TGFβ and IL-10 
[24], retinoic acid [25], LPS [26], monophosphoryl lipid A 
[27] and annexin-coated particles [28], all with similar effi-
cacy. However, the stability of tolDC in vivo, could not be 
guaranteed [20], hence, this is currently considered the most 
important factor in bringing tolDC therapy to the clinic.
To date, three main DC subsets are recognised: conven-
tional (c)DC1  (CD11cintCD11blo/negCD8a+CD103+), cDC2 
 (CD11chiCD11bhiCD103−CD8a−) and plasmacytoid (p)
DC  (CD11c−CD11b−B220+SiglecH+) [29–32]. Standard 
GM-CSF bone marrow cultures result in a heterogeneous 
population of mostly  cCD11b+ cDC2 and macrophages [30]. 
However, problematically, markers which characterise cDC2 
are also expressed on other immune cells. Hence, refining 
protocols to simultaneously allow in-depth characterisation, 
and improved isolation of tolDC for in vivo use is a key chal-
lenge. To address this, and produce an enriched population 
of tolDC, we have developed a modified cell culture protocol 
[33] which includes characterisation of bone marrow tolDC 
using the specific DC transcription factor Zbtb46 [34, 35]. 
The procedure involves initial depletion of  Lin+ cells and 
minimal handling/cell sorting, thus maximising the yield of 
tolDC and avoiding induction of immunogenic mDC.
Conversion of tolDC to mDC is accompanied by a shift 
from oxidative phosphorylation (OXPHOS/Krebs Cycle) 
and fatty acid oxidation to lactic acid production and reli-
ance on glucose as the predominant carbon source [36] to 
generate ATP. Therefore, manipulation of these pathways 
to maintain DC OXPHOS and FAO has been proposed as a 
method to induce stable tolDC [37].
Previous studies have shown that the glucose analogue 
2-DG, by competing for hexokinase [38] can block induction 
of mDC [39, 40] in vitro. Furthermore, 2-DG is effective 
in downregulating immune responses in vivo: treatment of 
mice with daily injections of 2-DG inhibited the develop-
ment of experimental autoimmune neuritis (EAN) [41]. 
However, a daily injection of 2-DG as a treatment regime in 
humans is not practical or safe.
Here we show that both glycolysis and OXPHOS metabo-
lism are temporarily blocked in resting tolDC treated with 
low-dose (2.5  mM) 2-DG (2-DGtolDC) in  vitro in the 
presence of 11 mM glucose. 2-DGtolDC failed to engage 
aerobic glycolysis when challenged with mycobacterial 
antigen (Mtb) but instead activated OXPHOS metabolism 
and led to reduced NFkB signalling. In addition, PDL-1 and 
SIRP-1α checkpoint molecule expression were increased in 
2-DGtolDC after Mtb challenge, while SIRP-1α dephospho-
rylation was prevented. We further show that a one-time 
adoptive transfer of 2-DGtolDC prevents induction of exper-
imental autoimmune uveoretinitis (EAU) in mice.
Materials and methods
Animal studies
All animal procedures had been approved by the University 
of Aberdeen Ethics Review Committee Board and were per-
formed under valid Project Licence (PPL60/4496) approved 
by the Home Office (UK) under the Animals (Scientific Pro-
cedures) Act 1986. C57BL/6 J and OT-II (DO11.10) mice 
were bred, maintained and housed at the Medical Research 
Facility, University of Aberdeen, UK. All mice were kept 
at 22 to 24 °C and 45–65% relative humidity on a 12 h 
light–dark cycle, with free access to standard chow diet and 
water.
Induction of EAU and grading of disease
Experimental autoimmune uveoretinitis was induced in 
C57BL/6 J mice as previously described [26]. Briefly, mice 
were immunised with interphotoreceptor retinol-binding 
protein (IRBP) peptide 1–20 (GPTHLFQPSLVLDMAKV-
LLD) (New England Peptide, Gardner, MA, USA) (500 μg/
mouse) emulsified in Complete Freund’s Adjuvant (CFA) 
containing 3.5 μg/ml of H37Ra (231131, Difco Laborato-
ries, MI, USA) Mycobacterium Tuberculosis extract (Mtb), 
injected subcutaneously (s.c.) to the hind limbs. Pertussis 
toxin (PTx; Health Protection Agency, Chorley, UK) 1 μg/
mouse was administered intraperitoneally (i.p.) at the same 
time. Clinical signs of disease (retinal vessel inflammation/
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vasculitis) were evaluated by fundoscopic examination 
using an otoscope light-based system as described [26]. Dis-
ease severity was graded using a clinical grading scale as 
described [42] with modifications [26]. Mice were humanely 
killed at stated times (see Results) using an approved Sched-
ule One method under the Animals (Scientific Procedures) 
Act 1986. Eyes were harvested, fixed in 2.5% glutaralde-
hyde, embedded in resin, sectioned, and stained with hae-
matoxylin and eosin (H&E). Sections (3 μm thick) of each 
globe were taken at several different levels. Disease severity 
was graded on a scale of 0–4 according to a semi‐quantita-
tive histological scoring system as described previously [26, 
43].
Bone marrow‑derived dendritic cell (BMDC) culture
Bone marrow was flushed from mouse hindlimb bones using 
RPMI-1640 GlutaMAX media (Gibco, Invitrogen, UK) con-
taining 1% Pen/Strep. Erythrocytes were lysed using Red 
Blood Cell Lysing Buffer (Sigma, UK) as per the manufac-
turer’s instructions. T cells, B cells and MHC class  II+ cells 
were depleted using sheep-anti-rat IgG coated Dynabeads 
(Invitrogen, Dynal, Oslo, Norway) and a cocktail of rat anti-
mouse antibodies against CD4 (553727, BD Bioscience, 
UK), CD8 (550281 BD Bioscience, UK), B220 (550286, 
BD Bioscience, UK) and MHC class II (MCA09, Serotec, 
UK). The remaining cells were re-suspended in complete 
RPMI-1640 GlutaMAX media (Gibco) containing 5% heat-
inactivated ultra-low IgG Foetal Calf Serum (Gibco), 1% 
Pen/Strep (Gibco), 1% NEAA (Gibco), 0.1% 2-mercaptoe-
thanol (Gibco), 1% sodium pyruvate (Gibco) and 10 ng/
ml GM-CSF (Miltenyi Biotec GmbH, Bergisch Gladbach, 
GER) (referred to as complete medium; cRPMI) and plated 
at 1.5 × 106 cells in 2 ml per well in 12-well plates [day 
(d) 0 of culture]. Non-adherent floating cells were removed 
by gently exchanging 50% and 75% of the medium, respec-
tively, for fresh cRPMI on d2 and d4 of culture. On d6 of 
culture, non-adherent cells were again removed by gentle 
pipetting and only the loosely adherent cell clusters were 
harvested. Those cells were then depleted of neutrophils 
and monocytes using IgG coated Dynabeads (Invitrogen) 
and anti-Ly6G/Ly6C (Gr-1) antibody (553122 BD Biosci-
ence). The remaining cells were plated at 1.5 × 106 in cRPMI 
(lacking sodium pyruvate) and cultured overnight prior to 
further use.
BMDC treatments and stimulations
For in vivo experiments BMDC were cultured in the pres-
ence of 30 μg/ml IRBP 1–20 peptide (GPTHLFQPSLVLD-
MAKVLLD; New England Peptide, Gardner, MA) for 24 h 
with or without the presence of 2.5 mM 2-DG to induce 
an antigen‐specific response. For in vitro cell phenotype 
analysis BMDC were cultured for 24 h at various concen-
trations of 2-DG (Sigma, UK) and subsequently analysed 
by flow cytometry. For western blotting experiments, the 
medium exchange took place on d2 and d4 of culture. On 
d5 after  Gr1+ cell depletion, BMDC were pre-treated with 
2-DG (2.5 mM) for 3 h prior to incubation with LPS (1 μg/
ml ultrapure lipopolysaccharide (LPS) (E. coli 0111:B4, 
catalog #tlrl-3pelps, InvivoGen, USA) for 1 h, or heat-inac-
tivated Mtb extract (Mycobacterium Tuberculosis H37Ra, 
Difco (BD Bioscience, USA) (15 μg/ml) for 24 h.
Enzyme‑linked immunosorbent assay (ELISA)
Media supernatants over 2-DGtolDC cultures with and with-
out Mtb-treatment were analysed for IL-10 and IL-12 con-
centrations using ELISA (R&D Systems Quantikine kits) 
according to the manufacturer`s instructions.
T cell proliferation assay
CD4+ T cells from spleens and lymph nodes of DO11.10 
(OT-II) mice were enriched by magnetic bead separation 
using a naïve  CD4+ T cell isolation kit (#130–104-453, 
Miltenyi Biotec, GER), according to the manufacturer’s 
instructions. After isolation T cells were stained with car-
boxyfluorescein succinimidyl ester (CFSE) (2.5 μM/ml; Inv-
itrogen, USA) and co-cultured with BMDC activated with 
1 μg/ml LPS for 3 h before co-culture for 72 h in 96-well 
plates in the presence of ovalbumin (OVA) peptide 323–339 
(#RP10610-5, GenScript, USA) at 1 μg/ml. After 72 h the 
cells were harvested and analysed by flow cytometry.
Flow cytometry
Cells were incubated with fixable viability dye (eFluor 
455UV; eBioscience, UK) followed by CD16/CD32 
antibody (Fc-block; clone 2.4G2, BD Bioscience, 
UK), then stained with directly conjugated antibod-
ies (10  μg/ml and analysed using an LSR II device 
(BD Bioscience, UK). The following antibodies were 
purchased from BD Bioscience, UK unless stated oth-
erwise: MHC class II #553623, CD4 #552051, CD11b 
#550993, CD11c #550261, CD135 #562537, CD40 
#562846, CD86 #560581, CD25 #553866, CCR7 
#563596, PDL-1 #564716, Zbtb46 #565832, SIRP-1α 
#740159, c-kit #560185, CD115 #25–1152-82 (eBio-
science) and CX3CR1 #149023 (Biolegend). Tran-
scription factor buffer (BD Bioscience, USA, catalog 
#562574) was used in accordance with the manufactur-
er’s instructions to test for transcription factors. FlowJo 
software (TreeStar, Inc., Ashland, OR, USA) was used 
for data analysis.
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Metabolic studies
Cells were pre-treated with 2.5 mM 2-DG over 3 h, fur-
ther treated with Mtb (as applicable/specified), harvested by 
resuspension in PBS, two centrifugation/wash steps (5 min, 
300 g, 4 °C, PBS), and then homogenised/lysed at selected 
time points using the respective lysis buffer provided in 
each plate assay kit. The processed samples were centri-
fuged (5 min, 300 g, 4 °C) and supernatants collected in 
fresh tubes for analysis. The samples were tested for cellular 
uptake of glucose (cat no. ab102517), generation of pyru-
vate (cat no. ab65342), glucose-6-phosphate (G6P) (cat. no. 
ab83426), succinate (cat no. ab204718), and glycogen (cat 
no. ab65620), using colorimetric detection (Abcam, USA), 
performed as per the manufacturer’s instructions. Lactate 
dehydrogenase (cat no. ab102526) was quantified using a 
similar kit from the same provider.
Immunoblotting
Cells were homogenised in radioimmunoprecipitation-assay 
(RIPA) buffer containing sodium-orthovanadate and pro-
tease with phosphatase inhibitors. Proteins were separated 
by SDS-PAGE 4–12% gradient precast gels (Invitrogen, UK) 
and transferred to nitrocellulose membranes. All antibodies 
used for immunoblotting were purchased from Cell Signal-
ling Technology, MA, USA (unless otherwise stated): #8954 
phospho-tyrosine, #13379 SIRP-1α (pTyr-SIRP-1α), #4228 
phospho-PI3 kinase (PI3K) p85 (Tyr458), #4257 PI3K 
p85, #4060 phospho-AKT (Ser473), #4691 AKT, #3033 
phospho-NFκB p65 (Ser536), #8242 NFκB p65, #4810 
phospho-NFκB2 p100 (Ser866/870), #4882 NFκB2 p100/
p52, #5174 GAPDH. Immunoblots were visualised using 
enhanced chemiluminescence (PeqLab) and quantified using 
ImageJ.
Data analysis
Data are presented as mean ± SEM unless otherwise stated. 
Statistical analyses were conducted using one/two-way 
ANOVA, followed by Tukey post-hoc test using the Graph-
Pad Prism 7 software (GraphPad Software). Statistical sig-
nificance was assumed based on a 95% level of confidence.
Results
Altering the GM‑CSF bone marrow culture protocol 
to include depletion of  Lin+ cells produces 
an enriched tolDC population
Protocols for preparation of mouse BMDC have mostly 
aimed at high yield production of mDC as “cell vaccines” 
for therapy of cancer and infectious disease. Helft et al. 
selected MHC class  IIhiCD11chi cells – classical markers 
of mDC [30] – to study GM-CSF cultured BMDC by flow 
cytometry, while Jin et al. maximised the yield of MHC class 
 IIhi mDC by varying BMDC density in culture [44]. In both 
studies, there was significant “contamination” with non-
DC myeloid cells, identified as monocyte/macrophage type 
cells as well as myeloid precursor (MDP) cells. Few similar 
detailed phenotypic analyses of murine tolDC preparations 
have been performed [33, 44–46]. In part, this may be due 
to low expression of MHC class II by tolDC, hence MHC 
class II expression cannot be used to accurately identify 
tolDC populations. BMDC in the mouse are predominantly 
 CD11bhiCD11chi cDC2 [29, 47] and leave the bone marrow 
to enter the circulation as pre-DC, prior to populating the 
tissues and differentiating as either  CD4+ or  CD8+ tissue-
resident DC. Therefore, we used CD11b and CD11c expres-
sion for initial identification of BMDC.
The following is a phenotypic analysis of the total cell 
population in the bone marrow culture as prepared above 
and which was used in the studies described below. This 
preparation, which we term “tolDC”, was obtained after lysis 
of red blood cells, depletion of  Lin+ differentiated cells, fol-
lowed by harvesting loosely adherent cell clusters and fur-
ther depletion of Gr-1+ cells (neutrophils, and inflammatory 
monocyte-DC) from the culture at d6 [33]. No additional 
steps were taken in cell purification since it was recognised 
that this would reduce the overall yield of tolDC as well as 
lead to unwanted activation of the DC population, as detailed 
in the Introduction.
The preparation of tolDC contained an enriched population 
of  CD11bhiCD11chi cells (~ 55% of the total population) (Supp. 
Figure 1d) of which a proportion (~ 30%) expressed low/
intermediate levels of MHC class II (Fig. 1a-c) as described 
previously [33]. There were no MHC class  IIhi cells. In addi-
tion, the  CD11bhiCD11chi cell population expressed minimal 
levels of CD40 and CD86 and were mostly negative for the 
DC differentiation marker CD135 (Fig. 1, Supp. Figure 2). 
Importantly, 66% of the cells in the  CD11bhiCD11chi fraction 
were + ve for the definitive DC marker Zbtb46. A proportion 
of the non-CD11bhiCD11chi cell fraction, which consisted of 
 CD11blo/negCD11cneg cells (Supp. Figure 1d) also expressed 
Zbtb46 (~ 20%) (Fig. 1a-c).  CD11blo/negCD11cneg cells also 
expressed minimal levels of CD40 and CD86 and were mostly 
negative for the DC differentiation marker CD135 (Fig. 1, 
Supp. Figure 2). However, 56% of the  CD11blo/negCD11cneg 
cells (~ 25% of total tolDC preparation) expressed CD115, 
albeit at very low levels, indicating that these cells were at 
an earlier stage of myeloid cell development possibly at the 
MDP progenitor stage.  CD11blo/negCD11cneg cells were nega-
tive for the early haematopoietic stem cell (HSC) and for the 
GMP/MDP marker c-kit but contained a high percentage of 
the pre-DC marker CX3CR1 although at similar MFI to the 
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 CD11bhiCD11chi population (Supp. Figure 3). Overall, it 
was difficult to precisely define the developmental stage of 
the  CD11blo/negCD11cneg but it is likely that they contained a 
mixture of progenitor/pre-DC and pre-monocyte/macrophage. 
This is consistent with similar studies of GM-CSF-based prep-
aration of immunogenic DC in which MHC Class II was used 
to identify DC and in which there was a significant proportion 
of monocyte/macrophage precursor cells [30, 44]. In summary, 
the  CD11bhiCD11chi cell fraction of the tolDC preparation 
contained on average 66%  Zbtb46+ bona fide DC, while the 
final concentration of  Zbtb46+ DC in the tolDC preparation 
was ~ 45%. The Zbtb46 negative cells contained varying pro-
portions of myeloid cells at different stages of development.
Low‑dose (2.5 mM) 2‑DG does not affect tolDC 
viability
As indicated above, while tolDC have been investigated for 
their use in treating disease, previous work has found that 
they can be unstable and liable to activation (“maturation”), 
thus converting to mDC [48], likely due to exposure to pro-
inflammatory in vivo microenvironments. Since glycolysis 
underpins DC activation [39, 49] we investigated whether 
inhibition of glycolysis via 2-DG can stabilise tolDC and 
prevent their conversion to mDC when challenged.
Given that glucose is essential for DC survival, we first 
evaluated the effects of 2-DG on DC viability cultured in the 
presence of glucose (Supp. Figure 4). We found that high-
dose (10 mM) 2-DG treatment led to apoptosis in ~ 22% of 
DC (p < 0.05) while low doses (1 mM and 2.5 mM) had no 
significant impact on the number of cells becoming apop-
totic (Supp. Figure 4a, c). Furthermore, stimulation with 
Mtb (15 µg/ml) had no significant effect (Supp. Figure 4a, 
c). As expected, cells cultured in the absence of glucose 
became apoptotic at all doses (Supp. Figure 4b, d). Based 
on these results, we selected a dose of 2.5 mM 2-DG in 
glucose-containing media (11 mM) for all later experiments.
Fig. 1  Lin+ depletion of GM-
CSF bone marrow cultures 
generates an enhanced yield 
of resting tolerogenic (tol)DC. 
Cells were cultured as described 
in Methods and loosely adherent 
clusters harvested on d6 follow-
ing seeding on d0. Flow cytom-
etry analysis of live, single 
 CD11bhiCD11chi or remaining 
cells: a percentage of cells posi-
tive for MHC Class II (graph 
on left) and Mean Fluorescent 
Intensity (MFI) values for MHC 
Class II (graph on right), CD40, 
CD115 and CD135 surface 
markers, and the transcrip-
tion factor Zbtb46 gated on 
live, single  CD11bhiCD11chi 
cells (black bar) and  CD11blo/
negCD11cneg (white bar). b 
Representative corresponding 
MFI histograms for: MHC II, 
CD40, CD115, CD135, and 
Zbtb46, gated on live, single 
 CD11bhiCD11chi cells (top 
row) and  CD11blo/negCD11cneg 
(bottom row). c Representa-
tive flow cytometry dot plots 
for: MHC II, CD40, CD115, 
CD135, and Zbtb46, gated on 
live, single  CD11bhiCD11chi 
cells (top row) and  CD11blo/
negCD11cneg (bottom row). Error 
bars denote Standard Error of 
the Mean (SEM) with p values: 
*** < 0.001, **** < 0.0001, 
n = 4
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Low‑dose 2‑DG treatment enhances tolDC 
phenotype
Since the greater proportion of bona fide DC were contained 
in the  CD11bhiCD11chi fraction of the tolDC preparation 
(Fig. 1) the following analysis reports on the effects of 
2-DG on this fraction. Cells prepared in standard glucose-
containing (11 mM) cRPMI (see Methods) were treated on 
d6 of culture with 2.5 mM 2-DG for 24 h. This resulted in a 
15% reduction in  CD11bhiCD11chi-expressing cells (Fig. 2a, 
b). Similarly, there was a non-significant reduction in 
 Zbtb46+ cells in the  CD11bhiCD11chi cells to an average of 
40% which increased after additional stimulation with Mtb 
to ~ 70% (Fig. 2c). In contrast, 2-DG treatment reduced the 
percentage of  CCR7+ cells from ~ 80% to ~ 70% in both the 
Mtb-treated and -untreated  CD11bhiCD11chi fraction of the 
tolDC preparation (Fig. 2d). As discussed above, MHC class 
II is a core DC marker and the level of surface expression 
is reflective of the cells’ activation status. A proportion of 
 CD11bhiCD11chi cells (~ 25%) expressed low/intermediate 
levels of MHC class II rising to 50% following Mtb stimula-
tion (Fig. 2e). Importantly, 2-DG significantly reduced MHC 
class II expression in both the unstimulated (~ 15% average) 
and Mtb-stimulated (~ 22% average)  CD11bhiCD11chi frac-
tion (Fig. 2e) and prevented the Mtb-mediated upregulation 
of CD86 (Supp. Figure 2) while maintaining high levels of 
CX3CR1 (Supp. Figure 3c).
Our data suggest that the  CD11bhiCD11chi cells in the 
GM-CSF BMDC culture represent mostly a mix of MHC 
Class  IIlo/neg DC and  CX3CR1+ pre-DC typical of new 
entrants to the pool of circulating DC [50, 51]. Further-
more, we demonstrate that 2.5  mM 2-DG treatment of 
 Lin+-depleted, GM-CSF-cultured, Gr-1+ depleted BMDC 
cells yields an enriched population of stable tolDC contain-
ing ~ 40–60%  Zbtb46+, ~ 70%  CCR7+MHC class  IIlo/neg 
cells.
Antigen‑specific T cell proliferation in response 
to 2‑DGtolDC is reduced
We next wished to assess the T cell activation potential 
of 2-DGtolDC. Thus, we examined T cell proliferation 
using the OT-II transgenic mouse model which contains an 
enriched population of  CD4+ T cells expressing a TCR spe-
cific for the OVA 323–339 peptide (ISQAVHAAHAEINE-
AGR) [52]. T cells from lymph nodes and spleens of OT-II 
mice were labelled with CFSE and co-incubated with tolDC 
or 2-DGtolDC pulsed with OVA 323–339 peptide (1 µg/ml) 
and activated by LPS stimulation (1 µg/ml for 3 h). T cells 
were harvested after 72 h of co-culture and assessed for pro-
liferation. Unstimulated tolDC induced moderate levels of 
T cell proliferation (27.1%) which increased on activation 
of the DC with LPS (59.0%). In contrast, 2-DGtolDC failed 
Fig. 2  Treatment of bone marrow tolerogenic DC (tolDC) with 2-deoxy 
glucose (2-DG) results in an enhanced tolerogenic DC phenotype 
(2-DGtolDC). a BMtolDC were cultured as described and treated with 
2-DG (2.5 mM) (top panels), and/or stimulated with 15 µg/ml heat inac-
tivated mycobacterial extract, Mtb (bottom panels); representative plots of 
CD11b vs. CD11c (single, live cells) gating on  CD11bhiCD11chi cells and 
showing the percentage cell populations present within this gate; b histo-
grams of percentage gated single live  CD11bhiCD11chi cells as in Fig. 2a 
with or without 2-DG treatment and/or Mtb stimulation (n = 5); c the per-
centage of  Zbtb46+ cells in the gated  CD11bhiCD11chi population after 
treatment with 2-DG and/or stimulation with Mtb (n = 6) (left); represent-
ative dot plots of Zbtb46 gated on  CD11bhiCD11chi population (right); d 
expression of the chemokine receptor CCR7 on gated  CD11bhiCD11chi 
was significantly reduced after treatment with 2-DG (p < 0.001, n = 3), 
but unaffected by Mtb stimulation; representative dot plots of CCR7 gated 
on  CD11bhiCD11chi population (right); e gated  CD11bhiCD11chi cells 
exposed to Mtb alone increased expression of MHC class II as expected; 
in contrast, 2-DG treatment reduced expression of MHC Class II on 
untreated and Mtb-treated  CD11bhiCD11chi cells; representative dot plots 
of MHC Class II gated on  CD11bhiCD11chi population (right); (p values: 
* < 0.05, ** < 0.01, *** < 0.001 n = 4). Error bars in b-e denote Standard 
Error of the Mean (SEM)
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to induce significant T cell proliferation over baseline levels 
of T cells cultured without BMDC, even when they were 
activated with LPS (Fig. 3a, b).
TolDC surface expression of PDL‑1 and SIRP‑1α 
is increased by 2‑DG treatment
The binding of PDL-1 on DC to PD-1 on T cells classically 
transmits an inhibitory signal, leading to reduction of anti-
gen-specific T cell proliferation [53]. Given that 2-DGtolDC 
fail to induce appropriate proliferation of antigen-specific T 
cells we evaluated the expression of PDL-1 on 2-DGtolDC. 
Untreated tolDC expressed high levels of PDL-1 positivity 
both by cell number and MFI. These were further increased 
by 2-DG treatment (2.5 mM, 24 h) (93% vs. 82%, respec-
tively, p < 0.05), a difference which was more pronounced 
after stimulation with Mtb (Fig. 4a, b).
We also investigated the expression of a second immune 
checkpoint molecule, SIRP-1α [54], a known negative reg-
ulator of DC maturation [55] and mediator of DC and T 
cell homeostasis [56–58]. Flow cytometric analysis of sur-
face SIRP-1α revealed that treatment with 2-DG increased 
the number of cells expressing SIRP-1α from 39 to 57% 
(p < 0.001). In line with published literature, SIRP-1α sur-
face expression declined with Mtb stimulation but remained 
elevated in 2-DG treated cells (16% and 43.5% positive cells, 
respectively) (Fig. 4c). As for PDL-1 we conducted a time 
course of 2-DG treatment, finding that there was no increase 
in the percentage of cells expressing surface SIRP-1α in the 
first 6 h post-2-DG presence (in the absence of Mtb stimula-
tion). However, this was significantly increased at 24 h post-
treatment, with 39% of untreated cells and 63% of 2-DG-
treated cells expressing SIRP-1α (p < 0.001) (Fig. 4d). In 
addition, as for PDL-1, there was an increase in SIRP-1α 
MFI from 1 h.
Low‑dose 2‑DGtolDC produce less lactate at rest 
and shift to OXPHOS metabolism after stimulation 
with Mtb
Tolerogenic DC were incubated with 2.5 mM 2-DG in 
the presence of 11 mM glucose for 3 h and sequential cell 
lysates prepared for a time-course analysis of intracellular 
glucose and glucose metabolic products. In resting tolDC, 
treatment with 2-DG, caused up to 50% reduction in glucose 
uptake which reached its lowest level 15 min after exposure 
to 2-DG, returning to normal levels by 90 min (Fig. 5a). 
There was a corresponding reduction in lactate levels up 
to 90 min with a brief rise after 120 min (Fig. 5c). No sig-
nificant changes in pyruvate, glucose-6-phosphate (G6P), 
or lactate dehydrogenase were observed during this early 
exposure to 2-DG (Fig. 5b, e, f). There was a late reduction 
in lactate by 24 h (Fig. 5c). Reduced levels of succinate were 
observed at 15 and 60 min with a brief rise at 90 min. By 
24 h, intracellular succinate levels had declined almost to 
nil (Fig. 5g). There were also large swings in intracellular 
glycogen levels in 2-DGtolDC with a decline almost to nil 
at 15 min, a second small drop at 60 min and a sharp rise 
90 min after exposure of tolDC to 2-DG (Fig. 5d). After 
24 h, glycogen levels remained elevated in 2-DGtolDC.
These data suggest that both anaerobic glycolysis (vide 
lactate and LDH) and OXPHOS (vide succinate) metabolism 
are inhibited in low-dose resting 2-DGtolDC. In the case of 
anaerobic glycolysis, the effects lasted for 90 min. However, 
OXPHOS metabolism remained significantly reduced long 
after the effects of 2-DG had disappeared. In addition, the 
Fig. 3  LPS-activated, 2-DG-treated DC (2-DGtolDC) are poor stim-
ulators of T cell proliferation. Ovalbumin (OVA peptide)-specific 
OT-II cells were stimulated by OVA-pulsed 2-DG-treated and con-
trol untreated DC, with or without prior activation with LPS (1 µg/
ml) and T cell proliferation assessed using the CFSE dilution assay as 
described in Methods. Cells were harvested from the co-cultures after 
72 h and assessed for T cell proliferation by flow cytometry, gating 
on the T cell population. a Representative flow cytometry histograms 
of T cell proliferation. T cells cultured in isolation, did not proliferate 
(black shading), while T cells co-cultured with LPS-activated, OVA-
pulsed DC induced robust proliferative responses (blue shading). In 
contrast, T cells co-cultured with 2-DG-treated OVA-pulsed DC (red 
shading) proliferated only moderately compared to co-culture with 
untreated DC. b Quantitative analysis of T cell proliferation measured 
by CFSE dilution assay. Treatment of BMDC with 2-DG significantly 
reduced the induction of T cell proliferation by LPS-activated BMDC 
(*p < 0.05, **p < 0.01, n = 3)
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large swings in intracellular glycogen levels suggest that 
glycogen stores may provide fuel for cellular homeostasis 
during 2-DG-induced periods of relative glucose starvation.
Glycolysis and OXPHOS metabolism were markedly dif-
ferent in Mtb-stimulated 2-DGtolDC. High levels of intracel-
lular glucose were observed in 2-DGtolDC peaking 5 min 
after stimulation with Mtb and again at 90 min, suggesting 
an accumulation of unmetabolized glucose (Fig. 6a). Lactate 
production declined during the first 30 min but returned to 
baseline by 60 min and showed a small increase by 120 min 
before normalising once more by 24 h (Fig. 6c). This contrasted 
with non-2DG-treated cells which generated peaks of lactate 
production 5 min, 30 min and 120 min after Mtb stimulation 
(Fig. 6c). Lactate dehydrogenase levels remained unchanged 
throughout the period of observation (Fig. 6f). No early changes 
were noted in pyruvate or G6P levels in 2-DGtolDC although 
there was a late rise at 2 h in G6P levels, returning to normal 
by 24 h (Fig. 6e). Interestingly, there were two brief peaks in 
glycogen levels at 5 and 90 min in 2-DGtolDC but the late surge 
in glycogen seen in Mtb-stimulated non-2-DG-treated cells was 
not observed (Fig. 6d). There were also two peaks of increased 
succinate levels, in 2-DGtolDC after Mtb stimulation, one at 
5 min after exposure to 2-DG and a second at 90 min which 
coincided exactly with a similar peak in Mtb-stimulated non-
2-DG-treated cells.
These data indicate that Mtb stimulation of 2-DGtolDC 
in the presence of glucose failed to initiate expected levels of 
anaerobic glycolysis. Instead, glucose appeared to accumulate 
in the cell at 5 min and glycogen stores increased. Interestingly, 
unlike in resting cells, the early surge in OXPHOS metabolism 
Fig. 4  Expression of PDL-1 and SIRP-1α are increased in DC 
treated with 2-DG (2-DGtolDC). a Percentage of PDL-1+ DC, with 
or without 2-DG (2.5 mM over 24 h), and/or, stimulated with heat-
inactivated mycobacterial extract (Mtb, 15  μg/ml over 24  h) (gated 
on live, singlet,  CD11bhiCD11chi cells). Treatments are indicated by 
the ± matrix below graph. b Percentage of PDL-1+ DC treated with 
2-DG for 1/6/24 h. Below, histograms of PDL-1 expression intensity 
(MFI) for each time point are shown, with untreated DC in blue, and 
2-DGtolDC in red. Note increase in the intensity of PDL-1 expression 
in 2-DGtolDC. c Percentage of DC in live, singlet  CD11bhiCD11chi 
gate, that are positive for SIRP-1α, DC treatments/stimulations are 
indicated in the ± matrix. d Percentage of DC, treated with 2-DG 
for 1/6/24  h, positive for SIRP-1α. Below, histograms of SIRP-1α 
MFI for each time point are shown, with untreated DC in blue, and 
2-DGtolDC in red. Error bars denote Standard Error of the Mean 
(SEM), p values: * < 0.05, ** < 0.01, *** < 0.001, n = 3
2865Low‑dose 2‑deoxy glucose stabilises tolerogenic dendritic cells and generates potent in vivo…
1 3
(increase in succinate, 5 min) after Mtb stimulation suggests 
that relative glucose starvation due to 2-DG prevented Mtb-
induced anaerobic glycolysis but allowed OXPHOS metabolism 
to proceed. The second increase in succinate in 2-DGtolDC at 
90 min coincided with a similar increase in non-2-DG Mtb-
stimulated cells indicating that the early effects of 2-DG had 
died out, an interpretation of the data which was also supported 
by the late rise in G6P.
The data thus suggest that bone marrow pre-DC/tolDC as 
prepared here, and cultured in 11 mM glucose with 2.5 mM 
2-DG, convert to a stable tolDC phenotype, in which 
anaerobic glycolysis (vide lactate production) is blocked 
while OXPHOS metabolism (vide succinate production) is 
increased when the cells are challenged with Mtb protein. 
This altered metabolic phenotype coincides with the changes 
in DC surface markers and cell function as well as the sur-
face expression of checkpoint molecules induced by 2-DG as 
described in the previous sections. Low-dose 2-DG appears 
to re-programme resting tolDC to respond with an early 
shutdown of anaerobic glycolysis and a shift to OXPHOS 
metabolism when challenged with PAMPs such as Mtb and 
LPS (see below).
Fig. 5  Resting 2-DGtolDC have reduced levels of anaerobic gly-
colysis and OXPHOS metabolism. Graphs show the relative levels of 
intracellular glucose and glucose metabolites between untreated and 
2-DG-treated cells. BMDC were prepared as described, treated with 
2.5  mM 2-DG for 3  h, and lysed at different time points [0, 5, 15, 
30, 60, 90, 120 min and 1440 min (24 h) post-treatment] and tested 
with the respective plate assay kit (see Methods). Control cells were 
not treated with 2-DG. The relative levels of the various metabolites 
in control cells (blue lines) are shown in comparison with 2-DG-
treated cells (red lines): a after 15 min 2-DGtolDC contained ~ 45% 
less glucose than untreated DC; b no difference was observed in 
pyruvate levels; c a ~ 40% reduction in lactate was observed peaking 
at 30 min and a late increase in lactate levels was noted at 120 min 
2-DGtolDC; d glycogen levels dipped (15  min, 60  min) and rose 
(90 min) in 2-DGtolDC compared to controls; e and f there was no 
significant change in G6P and LDH levels between 2-DG-treated and 
-untreated DC; g early (15 min, 60 min) reductions in succinate levels 
with a later (90 min) rise followed by a marked late fall (24 h) were 
observed in 2-DGtolDC compared to untreated DC (all data from 
three replicates at each time point)
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2‑DG suppresses PI3K‑AKT and canonical NFκB 
signalling and enhances non‑canonical NFκB 
signalling in tolDC
Phosphorylated SIRP-1α (pSIRP-1α) is known to seques-
ter PI3K signalling in myeloid cells during TLR stimula-
tion [59] and to negatively regulate DC maturation [55]. 
We explored the possibility of direct effects of 2-DG on 
cell signalling, through this mechanism (Fig. 7). Tolero-
genic DC were pre-treated with 2-DG (3 h, 2.5 mM), and 
then stimulated with Mtb for up to 2 h (Fig. 7a) or for 24 h 
(Fig. 7b), following which pTyr-SIRP-1α was assessed by 
pTyr-immunoprecipitation, and western blotting for total 
SIRP-1α. SIRP-1α is constitutively phosphorylated in tolDC 
Fig. 6  Mtb-stimulated 2-DGtolDC fail to activate anaerobic metabo-
lism but engage OXPHOS. Graphs show the relative difference in 
intracellular glucose and glucose metabolites between tolDC (light 
blue line) and 2-DGtolDC (yellow line) after stimulation with heat-
inactivated mycobacterial extract (Mtb, 15  µg/ml). Dark blue line 
(baseline control) represents unstimulated non-2DG-treated con-
trol DC. a 2-DGtolDC showed a marked rise in intracellular glu-
cose levels 5  min after Mtb stimulation which declined between 
30 and 60  min and peaked again at 90  min; non-2-DG-treated DC 
showed a smaller late rise in glucose uptake at 90  min after Mtb 
stimulation; b there was no difference in pyruvate levels; c non-2DG-
treated DC showed increases in lactate at 5, 30 and 120  min while 
2-DGtolDC had a reduced level at 30 min and a late rise at 120 min; 
d 2-DGtolDC showed small rises in glycogen at 5 and 90 min while 
non-2-DG-treated DC had a marked late increase (~ × 10); e G6P was 
increased at 120 min in 2-DGtolDC and at 24 h in non-2-DG-treated 
DC after Mtb stimulation; G6P levels were increased in 2-DGtolDC 
120  min after exposure to 2-DG; f there was no difference in LDH 
levels; g there was an early increase (5  min) in succinate levels in 
2-DGtolDC compared to non-2-DG-treated DC after Mtb stimula-
tion while both 2-DG-treated and non-2-DG-treated DC had a similar 
marked late increase in intracellular succinate levels (90–120  min). 
Measurements were done in triplicate
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(see time point zero in Fig. 7a). In non-2-DG-treated tolDC, 
SIRP-1α is rapidly dephosphorylated within the first two 
hours following Mtb stimulation. In contrast, 2-DG-treated 
tolDC challenged with Mtb retain their pTyr-SIRP-1α levels 
(p < 0.001) (Fig. 7a). Furthermore, this effect is not only sus-
tained but increased up to at least 24 h (p < 0.001), by which 
time non-2-DG-treated tolDC have extremely low levels of 
pTyr-SIRP-1α after Mtb stimulation (Fig. 7b).
We next asked if sustained pSIRP-1α activity in 2-DG-
treated tolDC had a downstream effect on PI3K after stimu-
lation with Mtb. While there were no changes in p85 PI3K 
phosphorylation within the first two hours of Mtb stimula-
tion (Fig. 8a), we found that Mtb stimulation of non-2-DG-
treated tolDC induced high levels of p85 PI3K by 6 h which 
continued to increase up to 12 h. In contrast, 2-DGtolDC 
failed to induce any significant level of p85 PI3K (p < 0.001, 
2-DG-treated vs. non-2DG-treated tolDC) (Fig. 8b). The 
further downstream signalling component AKT followed 
a similar pattern, with no significant change in phospho-
rylation status within the first 2 h of stimulation with Mtb 
(Fig. 8c) but a significantly reduced level at 4 h (p < 0.05, 
2-DG-treated vs. non-2DG-treated tolDC) (Fig. 8d) lasting 
till 8 h post-stimulation.
Since PI3K and AKT signal downstream to activate NFκB 
[60], we further investigated the effects of 2-DG on NFkB 
signalling in tolDC. 2-DGtolDC failed to activate NFkB 
even when stimulated by Mtb. Stimulation with Mtb induced 
minimal levels of p-p65 S536 at any time from 2 to 12 h 
following stimulation with Mtb (p < 0.001) (Fig. 8e, f). In 
contrast, p-p100 was significantly increased in 2-DGtolDC 
in the first 2 h (p < 0.001) (Fig. 8g). We also found that total 
levels of p100 increased in 2-DG tolDC, but not in untreated 
tolDC, the levels peaking at 4 h (p < 0.001) and followed by 
a rapid decline (Fig. 8h). There was a concomitant increase 
in p52 expression from 4 h onwards in 2-DG-treated tolDC, 
while untreated control tolDC had consistently low expres-
sion over the 12 h period (p < 0.001) (Fig. 8i). These data 
show that, while canonical NFκB signalling is repressed 
in 2-DG-treated DC, non-canonical p100 is activated, and 
cleaved into transcriptionally active p52.
To demonstrate a downstream effect of 2-DG on cytokine 
signalling by tolDC we also performed an ELISA analysis 
of tolDC IL-10 and IL-12 secretion by assaying the super-
natants from cultured tolDC. As shown in Fig. 8j, IL-10 
secretion by Mtb-stimulated tolDC was markedly increased 
by exposure to 2-DG while the reverse was true for IL-12.
The data in Figs. 7 and 8, therefore, suggest that sus-
tained, upregulated hyperphosphorylation of SIRP-1α by 
2-DG stabilises tolDC function by preventing TLR-induced 
proinflammatory PI3K and NFκB activation while promot-
ing anti-inflammatory non-canonical NFκB activity and 
increased IL-10 production.
A single treatment with 2‑DGtolDC protects 
against experimental autoimmune uveitis (EAU)
Given the stable tolerogenic phenotypic and in vitro immu-
nosuppressive effects of 2-DGtolDC, we next determined 
if 2-DGtolDC can exert in vivo tolerogenic effects using 
the inducible EAU murine model of ocular inflammatory 
disease. IRBP-peptide primed tolDC (30 μg/ml) treated 
with 2.5 mM 2-DG for 24 h (1 × 106 cells in 100 µl PBS) 
were injected s.c. into C57BL/6 J mice and compared with 
untreated IRBP-peptide primed tolDC and PBS vehicle 
alone. Uveitis was induced 24 h later by immunising mice 
with IRBP peptide 1–20 (500 µg/mouse in 100 µl), emulsi-
fied in CFA containing 3.5 μg/ml Mtb, and simultaneous i.p. 
injection of PTx. Signs of clinical disease were assessed by 
Fig. 7  2-DGtolDC fail to dephosphorylate SIRP-1α after Mtb stimu-
lation.  Lin+-depleted bone marrow tolerogenic DC (BMtolDC) were 
cultured for 5  days in GM-CSF-containing cRPMI media (10  ng/
ml), Gr-1+ cells were depleted, and the tolDC cultured on d6 for 3 h 
with or without 2.5 mM 2-DG. They were then stimulated with heat-
inactivated mycobacterial extract (Mtb, 15 μg/ml) for the time shown 
(0–120 min, or 0–24 h) and assessed for SIRP-1α. a Immunoblots of 
tyrosine phosphorylated and total SIRP-1α, 0–120 min. Phosphoryla-
tion was evaluated by immunoprecipitation (IP) of phospho-tyrosine 
(pTyr) proteins and immunoblotting with total SIRP-1α protein; 
below, pre-IP samples probed for SIRP-1α total protein are shown 
to demonstrate equal input into IP. Quantification of pTyr-SIRP-1α 
values are presented as the [phospho:total] ratio; 2-DGtolDC are 
shown in open circles, untreated DC in filled circles. Times refer to 
post-Mtb stimulation. b pTyr-SIRP-1α (measured by pTyr IP), at 0 
and 24 h with and without Mtb stimulation (n = 3 for each condition). 
2-DG prevented the downregulation of pTyr-SIRP-1α induced by Mtb 
stimulation at 24 h in BMDC. Quantification of pTyr-SIRP-1α values 
shown as for a; Immunoblots were visualised using enhanced chemi-
luminescence (PeqLab) and quantified using ImageJ
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fundoscopy [26, 42] at d14, 21 and 28 post-inoculation and 
histological eye exams performed at d28.
Clinical signs of EAU developed in mice injected with 
either PBS or with untreated tolDC, observed as white 
retinal infiltrates and vasculitis which increased in severity 
and extent through d14, 21 and 28. However, mice injected 
with 2-DGtolDC developed no evidence of disease at d14 
and 21, with only occasional small infiltrates evidenced at 
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d28 (Fig. 9a). There was no significant difference in disease 
severity in mice that received PBS (mean Clinical Score, 
CS, 1.5) or untreated tolDC (CS, 1.5) at d21 and 28 post-
immunisation. However, mice injected with 2-DGtolDC had 
significantly reduced clinical scores (CS 0.5) (p < 0.001: 
PBS vs. 2-DG-treated) (Fig. 9a, b) at these times.
Histology examination of the eyes at d28 confirmed the 
fundus findings with evidence of immune cell infiltration, 
granuloma development and damage to retinal tissue in 
control (PBS-injected) mice, and in mice given non-2-DG-
treated tolDC (Fig. 9c, d). Mean severity grade (see Meth-
ods) was 1.5 for PBS-injected mice, and 1.25 for mice given 
non-2DG-treated tolDC. In contrast, mice given 2-DGtolDC 
had minimal signs of inflammation with an average histo-
logical score of 0.25, no visible granulomas or tissue damage 
and scarce, scant immune cell infiltrates mostly restricted 
to the vitreous cavity (Fig. 9c, d). These data showed that a 
single s.c. injection of 2-DGtolDC was sufficient to prevent 
induction of EAU, indicating a profound stable (> 28 days, 
duration of observation) in vivo tolerogenic effect.
A graphical summary of the data in this paper is pre-
sented in Supp. Figure 5.
Discussion
Targeting glucose metabolism in immune cells is an attrac-
tive approach to manipulating immunity [61]. In this regard, 
inhibition of glycolysis has been reported to suppress 
immune reactions, including autoimmune responses, in 
experimental animals principally by systemic administra-
tion of glycolytic inhibitors such as 2-DG and 3-bromopyru-
vate [41, 62, 63]. However, since this approach targets sev-
eral types of immune cells it is difficult to be sure which 
component(s) of the immune response are modified and so 
the precise mechanism of action remains obscure. In addi-
tion, on a more practical level, daily administration of 2-DG 
might be difficult to translate to clinical use if only because 
of potential side effects of long-term administration.
Here, we adopt a different approach using glycolysis inhi-
bition of ex vivo DC to enhance and stabilise their tolero-
genic properties prior to adoptive transfer. We describe a 
procedure based on previous work [17, 33, 45, 64, 65] for 
preparation of mouse tolDC comprised of a mixed popu-
lation of myeloid cells containing preDC/tolDC and MDP 
monocyte/macrophages. Treatment of this cell preparation 
with low-dose 2-DG (2.5 mM) stabilises an enriched popu-
lation (up to 60%) of  Zbtb46+ cells within the major sub-
set of MHC class  IIlo/neg  CD11bhi  CD11chi tolDC (Fig. 2c). 
Antigen-specific T cell proliferation was reduced in response 
to activation by peptide primed 2-DGtolDC (Fig. 3) and 
2-DGtolDC preferentially secreted IL-10 rather than IL-12 
after activation by Mtb (Fig. 8). Remarkably, a single inoc-
ulation of 1 × 106 2-DGtolDC was enough to prevent the 
development of the inducible murine autoimmune disease 
EAU for up to 28 days (duration of the experiment), con-
firming that 2-DGtolDC are stable in vivo and induce a pro-
longed immunosuppressive effect (Fig. 9).
Glucose metabolism is central to DC function [49]. Basal 
oxidative phosphorylation (OXPHOS) is the main source of 
energy for resting DC, undifferentiated DC and tolDC [66] 
and is regulated by miR-142 [67]. The energy required for 
conversion of resting, undifferentiated DC to mDC after chal-
lenge is underpinned by a metabolic switch from OXPHOS 
metabolism to anaerobic glycolysis, a process necessary for 
antigen presentation to T cells [19, 36, 37, 68–71]. In the 
present study, 2-DG treatment of resting/tolDC downregu-
lated basal OXPHOS metabolism without inducing lactate 
production (Fig. 5). Challenge of 2-DGtolDC with Mtb also 
failed to initiate anaerobic glycolysis but instead upregulated 
an early increase in succinate production thus favouring 
OXPHOS metabolism (Fig. 6). Furthermore, a second phase 
of anaerobic glycolysis, seen in untreated tolDC at 120 min 
after challenge with Mtb, was much reduced in 2-DGtolDC 
while OXPHOS metabolism occurred in both 2-DG-treated 
and -untreated Mtb-challenged DC around this time (Fig. 6). 
These data suggest that tolDC treated with 2.5 mM 2-DG 
in the presence of 11 mM glucose are programmed prefer-
entially to block anaerobic metabolism and instead sustain 
OXPHOS metabolism when challenged. Under these con-
ditions, OXPHOS metabolism may simply be the default 
pathway for handling glucose. Importantly 2-DG, at the 
Fig. 8  2-DGtolDC show reduced pro-inflammatory PI3K-AKT and 
canonical NFκB signalling after Mtb stimulation with increased 
non-canonical NFκB signalling. TolDC were prepared as indi-
cated in legend to Fig. 7. Cells were cultured on d6 for 3 h with or 
without 2.5  mM 2-DG. They were then stimulated with heat-inac-
tivated mycobacterial extract, Mtb (15  μg/ml) for the times shown 
(0–120  min, or 0–12  h) and assessed for signalling components; 
immunoblots with corresponding graphical quantifications are shown: 
a Phosphorylation of PI3K-p85 at Y485, 0–120 min with total p85; 
quantification of PI3K-p85 Y485 0–120  min. b PI3K-p85 phospho-
rylation at 0–12 h; quantification of PI3K-p85 0–12 h. c Phosphoryla-
tion of AKT at S473 0–120 min, total AKT control is shown; quanti-
fication of AKT S473 0–120 min; d AKT S473 0–12 h; quantification 
of AKT S473 0–12 h; e NFκB p65 S536 0–120 min and total NFκB; 
quantification of p65 S536 0–120 min. f p65 S536 0–12 h; quantifica-
tion of p65 S536 0–12 h; g Phosphorylation of NFκB p100 S866/870, 
with total p100 control 0–120 min; quantification of p100 S866/870; 
h Total p100 0–12  h; quantification of p100 relative to GAPDH 
loading control; i Total p52 0–12  h; quantification of p52 relative 
to GAPDH loading control. 2-DGtolDC are shown in open circles, 
untreated DC in filled circles. Error bars denote Standard Error of 
the Mean (SEM), p values: * < 0.05, ** < 0.01, *** < 0.001, n = 3. j 
2-DGtolDC show increased IL-10 and decreased IL-12 secretion. 
Media supernatants were removed at 0, 6 and 12 h post-Mtb stimula-
tion (15 µg/ml), with and without 2.5 mM 2-DG from cells. Superna-
tant was then assayed via ELISA for IL-10 and IL-12 concentration. 
n = 3/genotype. p values: * < 0.05, ** < 0.01, **** < 0.0001
◂
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optimal concentration of 2.5 mM, did not induce apoptotic 
cell death in resting or Mtb-challenged tolDC cultured in 
glucose-containing (11 mM) conditions. Competition for 
uptake between glucose and 2-DG and for interaction with 
intracellular hexokinase thus appeared to favour 2-DG since 
there was potentially four times more glucose available to 
the cell than 2-DG. Interestingly, 2.5 mM 2-DG not only 
inhibited Mtb-induced anaerobic glycolysis but prevented 
glycogen accumulation indicating that glucose metabolism 
overall was dysregulated in 2-DG-treated cells. It has been 
shown that intrinsic glycogen stores and glycogenolysis are 
necessary for full TLR activation of mDC and T cell acti-
vation [72] which may thus explain some of the effects of 
2-DGtolDC on T cell proliferation reported here. Resting 
DC treated with 2-DG expressed the surface characteristics 
of bona fide tolDC: i.e. low/absent expression of MHC class 
II, reduced expression of CD86, lack of CD40 expression 
(Supp. Figure 2a-c and Fig. 1) and close to 100% expres-
sion of PDL-1 (Fig. 4). Even when stimulated with Mtb 
there was no significant upregulation of MHC Class II on 
2-DGtolDC unlike that seen with untreated Mtb-challenged 
tolDC (Fig. 2e). 2-DGtolDC also failed to upregulate CD86 
after Mtb stimulation (Supp. Figure 2). These data confirm 
the stability and “maturation resistance” of 2-DGtolDC.
The effects of 2-DG on glucose metabolism in tolDC as 
administered here are transient and can be explained by the 
known half-life of 2-DG. A ratio of glucose to 2-DG in the 
medium (~ 4:1, see above paragraph) is such that when the 
effect of 2-DG has declined (0 →  ~ 60 min, short half-life) 
the cells shift back to full glucose utilisation. In non-Mtb 
treated, non-activated cells which process glucose through 
pyruvate into the Krebs cycle and on to OXPHOS, succinate 
levels are sustained throughout the period in the presence 
of 11.0 mM glucose (normal conditions for quiescent DC). 
The competition between 2-DG and glucose for Glut-1 and 
hexokinase activity means that only partial aerobic glyco-
lysis can be achieved. At the same time, because glucose 
metabolism is reduced, Krebs cycle metabolism is also 
reduced for up to 90 min, coinciding with the decline in 
2-DG. At 90 min, there is a slight increase in succinate pro-
duction (1.3-fold, Fig. 5g) but this eventually ceases alto-
gether by 24 h. The storage of glycogen (Fig. 5d) [72] is a 
known survival behaviour of DC. In Mtb-activated cells, 
when the glucose flux is increased by increased energy 
demands [73], 2-DG treatment leads to a marked increase 
in succinate accumulation (Krebs cycle activity) in the early 
phase because aerobic glycolysis is reduced to < 70% by 
30 min (Fig. 6c). Accumulation of succinate declines as the 
effect of 2-DG wears off (30–60 min) but increases for both 
2-DG-treated and -untreated Mtb-activated DC as the cells 
revert to normal glucose utilisation (90 min–24 h).
Despite the transient nature of 2-DG on tolDC metabo-
lism in the protocol described here, the effect of 2-DG is to 
stably re-programme the cells for tolerogenicity. Tolerogenic 
DC as a potential therapeutic intervention for autoimmune 
disease and transplant rejection have been studied exten-
sively (reviewed in [74, 75]). Various methods had been 
explored both experimentally and clinically to generate 
Fig. 9  A single subcutaneous inoculation of mice with 2-DG-treated 
DC (2-DGtolDC) prevents the development of EAU. Bone marrow 
tolerogenic DC (BMtolDC) were prepared as described in Methods 
and cultured for 24 h with or without 2.5 mM 2-DG in the presence 
of interphotoreceptor retinol-binding protein (IRBP) peptide (30 μg/
ml). 1 × 106 cells suspended in 100  µl of PBS were inoculated sub-
cutaneously (s. c.) to the neck. 24  h later, IRBP peptide (500  µg/
mouse) was emulsified in Complete Freund’s Adjuvant (CFA) con-
taining 3.5 μg/ml of Mtb extract, and injected s.c. at the hind limbs. 
Pertussis toxin (1 μg/mouse) was administered intraperitoneally (i.p.) 
at the same time. Mice treated with untreated tolDC, 2-DGtolDC and 
vehicle (PBS) were compared for clinical signs of eye disease. a Rep-
resentative fundus images of mice inoculated with either untreated 
tolDC, PBS (negative control), or 2-DGtolDC (2.5  mM over 24  h). 
White sheathing surrounding the vessels indicates widespread vascu-
litis with onset at d14. Black arrows indicate patches of granuloma-
tous inflammation. Note absence of disease in 2-DGtolDC-treated 
mice apart from a localised single lesion at d28; b Fundus images 
were randomised and scored by two masked independent graders, 
according to our previously reported Clinical Score (CS) criteria; see 
Methods (n = 36 mice per group); c Representative histology images 
of the posterior segment of mice eyes 28 days post-inoculation. Mice 
inoculated with PBS (control) or with untreated DC show evidence of 
moderate to severe retinal inflammation with vasculitis, retinal folds, 
granulomas and vitreous cell infiltrates. In contrast, mice treated with 
2-DGtolDC have normal retinal morphology. d Semi-quantitative 
masked grading of histological sections (see Methods) (n = 6 mice per 
group), untreated DC (black), PBS (red) and 2-DGtolDC (blue) [26]. 
Resin embedded sections were stained with haematoxylin and eosin. 
Scale bar = 100  μm. Error bars denote Standard Error of the Mean 
(SEM), p values: * < 0.05, ** < 0.01, *** < 0.001
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tolDC including VitD/dex [18–23], inhibition of mTOR 
[76], retinoic acid treatment [25], activation of the IDO/
ARH system [77, 78], LPS/TLR4 ligation/monophosphoryl 
lipid A [6, 26, 79] and cytokine treatment (IL-10, IL-27, 
TGFβ (reviewed in [74, 80]). Much work has been done 
to generate stable DC which would have reduced risk of 
becoming activated in vivo, currently considered one of the 
main stumbling blocks to successful tolDC therapy for auto-
immune disease [18, 81]. Tolerogenic DC are characterised 
by expressing reduced levels of one or more of the family 
of proteins which comprise the transcription factor NFkB, a 
core inducer of proinflammatory cytokines [82] while direct 
inhibition of NFkB in DC is currently under investigation as 
a method of preparing tolDC [7]. However, the precise role 
of NFkB proteins in DC may be quite subtle and variable 
in different subsets of DC, since they regulate migratory 
DC which promote tolerance to self-antigens and immune 
homeostasis generally [4, 83]. Tissue-resident non-activated 
sessile preDC/tolDC thus appear to have a basal “constitu-
tive” level of NFkB activity.
Here we show that in vitro 2-DGtolDC express reduced 
levels of NFkB p65 in response to stimulation with Mtb as 
well as increased levels of the non-canonical anti-inflam-
matory p100/p52 transcription factors (Fig. 8h, i). Reduced 
levels of NFkB may be a downstream effect of inhibition of 
PI3K/AKT signalling events induced by exposure of DC to 
2-DG (Fig. 8a-d) but this would not account for the early 
onset (15 min) of reduction in NFkB signalling which pre-
cedes reduced PI3K/AKT signalling. In fact, the constitutive 
basal levels of p65 signalling in resting DC is almost com-
pletely abrogated simply by the exposure of DC to 2-DG for 
3 h (Fig. 8g, h). It would thus appear that reduced NFkB sig-
nalling is a direct consequence of sustained 2-DG OXPHOS 
metabolism and the prevention of anaerobic metabolism 
(vide lactate production) which is characteristic of tolDC as 
generated through other means (reviewed in [66]).
If NFkB inhibition is a central mechanism for tolDC func-
tion, keeping NFkB in check might be important for stabilis-
ing and sustaining tolDC activity for instance in the produc-
tion of IL-10 (Fig. 8j). Tolerogenic DC are characterised 
by expression of a range of checkpoint molecules including 
PDL-1 and SIRP-1α. PDL-1 on DC is considered to be a 
major inducer of  TREG via its ligation of PD-1 on T cells 
and has been shown to inhibit experimental autoimmune 
encephalomyelitis (EAE) [84]. In the current experiments, 
PDL-1 expression on pre-DC/tolDC was high both in the 
percentage of cells and intensity of expression (MFI) and 
was further increased by treatment with 2-DG (Fig. 4a, b). 
Moreover, the challenge with Mtb did not decrease PDL-1 
expression in 2-DGtolDC.
SIRP-1α is also recognised as a major immune checkpoint 
molecule on DC [54, 85] although it has also been proposed 
to have a pro-inflammatory role in a model of colitis [86] 
and a regulatory role in autoimmune diabetes [87]. SIRP-1α 
is constitutively expressed on DC presumably by its default 
binding to various ligands either on adjacent cells (CD47) or 
to extracellular matrix components such as thrombospondin 
(for review see [88]). Conventional cDC1 SIRP-1α+ cells are 
required for central tolerance induction [89] while recently it 
has been shown that human SIRP-1α+ cDC2 occupy specific 
locations in their role in immune surveillance and have been 
described as the “guardians of the mucosa” [90].
SIRP-1α is phosphorylated in its native state in tolDC 
(see time point zero, Fig. 7a) and does not require ligation to 
CD47 to be phosphorylated [91]. It is rapidly dephosphoryl-
ated e.g. after the challenge of DC with Mtb (Fig. 7a) with 
extensive loss of surface expression (Fig. 4c). Treatment of 
DC with 2-DG prevents both these effects (Figs. 4c, 7a). 
Phosphorylated SIRP-1α is known to sequester AKT [59] 
which, following activation of PI3K, signals upstream of 
NFkB [92, 93]. PI3K/AKT signalling is a central signalling 
pathway in TLR activated DC [92] and culminates in NFkB 
nuclear translocation and signalling [26]. The sequestration 
of AKT by pSIRP-1α in 2-DGtolDC would thus stabilise 
tolDC function by prolonging the inhibition of NFkB and 
more importantly prevent P65NFkB activation after chal-
lenge with, for instance, Mtb. We thus propose that 2.5 mM 
2-DG treatment of pre-DC/tolDC enhances and stabilises 
their tolerogenicity by direct inhibition of NFkB signal-
ling in the immediate phase of antigen/pathogen challenge 
via inhibition of anaerobic glycolysis while preventing the 
second phase NFkB activation through sustained pSIRP-1α 
activity and sequestration of upstream PI3K/AKT.
The effects of 2-DG on the role of PDL-1 in tolDC may 
be more complex. High expression of PDL-1 is characteris-
tic of tolDC and its expression was increased in 2-DGtolDC 
(Fig. 4a, b). Immune cells convert phosphoenol-pyruvate 
to pyruvate during the last step of aerobic glycolysis using 
pyruvate kinase of which isoforms PKM1 and PKM2 may 
be active. Immune cells generate large amounts of pyruvate 
for OXPHOS and for anaerobic glycolysis to supply acute, 
as well as storage, energy needs mostly using tetrameric 
PKM1. PKM1 and PKM2 activity, however, are mutually 
exclusive and PKM2 is considered to be a metabolic sensor 
responding to glucose starvation [94, 95]. In cancer cells, 
PKM2 is regulated by protein arginine N-methyl trans-
ferase (PRMT), a process which can be prevented by 2-DG. 
PKM2 exists as a monomer/dimer and translocates to the 
nucleus to stimulate HIF1α transactivation domain function 
and recruitment of p300 HIF1α and other genes involved 
in glycolysis, for instance in inflammatory macrophages 
[96]. PKM2 is also required for expression of LPS-induced 
PDL-1 in macrophages [97] while activation of PKM2 in 
DC inhibits activation of Th1 and Th17 cells and suppresses 
EAE [98] indicating an indirect immunoregulatory role for 
PKM2. When PKM2 is converted to a tetramer for instance 
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by tetraethyl pyrophosphate (TEPP), it cannot translocate to 
the nucleus and glycolysis is inhibited [97, 98]. It is, there-
fore, unclear how PKM2 can orchestrate an immunoregula-
tory role e.g. via PDL-1 expression on DC while promoting 
an immunogenic role via ramping up glycolytic activity. This 
may depend on the timing and context of PKM2 activity and 
requires further study. With regard to the effects of 2-DG, 
activation of PKM2 sensitises cancer cells to 2-DG [99] and 
it is likely that a similar sensitisation occurs in tolDC. Par-
ticularly, low-dose 2-DG (2.5 mM) hexokinase II-generated 
2-DG6P may be sufficient to permit continuing expression 
of PDL-1 but insufficient to permit full-throttle HIF1α gene 
expression and lactate production.
Whatever the specific mechanism, the aim of generat-
ing protocols for tolDC is to bring this potentially valuable 
therapeutic intervention to the clinic. Several methods are 
under investigation in clinical trials including Vit/dex [6, 
18], LPS/MPLA [27, 100], as well as direct inhibition of 
NFkB (liposomes) and inhibition of mTOR as detailed 
above. Vit/dex treatment of DC induces glycolysis and 
OXPHOS metabolism and inhibits NFkB while inhibition 
of mTOR can have pro- and anti-inflammatory effects. None 
of these methods has shown efficacy in clinical trials, as yet, 
and the question has been raised as to whether these are fea-
sible treatments [101]. We show here that ex vivo treatment 
of pre-DC/tolDC using low-dose (2.5 mM 2-DG) gener-
ates enhanced stable tolDC which prevents an experimental 
autoimmune disease (EAU), and this simple approach has 
potential for ready translation to the clinic.
Acknowledgements We thank the University of Aberdeen Iain Fraser 
Flow Cytometry core facility, and the University of Aberdeen Histol-
ogy and Microscopy core facility for processing of histology slides. 
The authors thank University of Aberdeen Medical Research Facility 
for technical assistance with in vivo experiments. We thank Dr. Tian 
Yu, Dr. Yi-Hsia Liu, Mrs Rosemary Fordyce, and Mrs Elizabeth Muck-
ersie for technical assistance with in vivo and in vitro experiments.
Author contributions MC, SLS, LK and JVF designed the experi-
ments; MC, SLS, CM and JVF wrote the manuscript; MC, IPK and 
LK performed in vivo experiments and analysis; SLS performed immu-
noblotting and ELISA experiments and analysis; MC performed flow 
cytometry experiments, metabolic studies and analysis; CM, LK and 
JVF discussed data and hypotheses and reviewed the manuscript. All 
authors reviewed and edited the manuscript before submission.
Funding This work was supported by funds from the University of 
Aberdeen Development Trust Grants RG14251 and RG12663. Maria 
Christofi was the recipient of a University of Aberdeen PhD Student-
ship. Samantha Le Sommer was funded by a Wellcome Trust ISSF 
Postdoctoral Fellowship.
Compliance with ethical standards 
Conflicts of interest The authors declare there are no conflicts of inter-
est.
Ethics approval All animal procedures had been approved by the 
University of Aberdeen Ethics Review Committee Board and were 
performed under valid Project Licence (PPL60/4496) approved by the 
Home Office (UK) under the Animals (Scientific Procedures) Act 1986.
Availability of data and material All original data/generated material 
will be made available upon request.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Steinman RM (2012) Decisions about dendritic cells: past, 
present, and future. Annu Rev Immunol 30:1–22. https ://doi.
org/10.1146/annur ev-immun ol-10031 1-10283 9
 2. Schlitzer A, McGovern N, Ginhoux F (2015) Dendritic cells 
and monocyte-derived cells: two complementary and integrated 
functional systems. Semin Cell Dev Biol 41:9–22. https ://doi.
org/10.1016/j.semcd b.2015.03.011
 3. Schlitzer A, Zhang W, Song M, Max X (2018) Recent advances 
in understanding dendritic cell development classification and 
phenotype. Res Faculty Rev. https ://doi.org/10.12688 /f1000 resea 
rch.14793 .1
 4. Baratin M, Foray C, Demaria O, Habbeddine M, Pollet E, Mau-
rizio J, Verthuy C, Davanture S, Azukizawa H, Flores-Langarica 
A, Dalod M, Lawrence T (2015) Homeostatic NF-kappaB signal-
ing in steady-state migratory dendritic cells regulates immune 
homeostasis and tolerance. Immunity 42(4):627–639. https ://doi.
org/10.1016/j.immun i.2015.03.003
 5. Schraml BU, Reis E, Sousa C (2015) Defining dendritic cells. 
Curr Opin Immunol 32:13–20. https ://doi.org/10.1016/j.
coi.2014.11.001
 6. Bell GM, Anderson AE, Diboll J, Reece R, Eltherington O, 
Harry RA, Fouweather T, MacDonald C, Chadwick T, McColl 
E, Dunn J, Dickinson AM, Hilkens CM, Isaacs JD (2017) Autol-
ogous tolerogenic dendritic cells for rheumatoid and inflam-
matory arthritis. Ann Rheum Dis 76(1):227–234. https ://doi.
org/10.1136/annrh eumdi s-2015-20845 6
 7. Benham H, Nel HJ, Law SC, Mehdi AM, Street S, Ramnoruth 
N, Pahau H, Lee BT, Ng J, Brunck ME, Hyde C, Trouw LA, 
Dudek NL, Purcell AW, O’Sullivan BJ, Connolly JE, Paul SK, 
Le Cao KA, Thomas R (2015) Citrullinated peptide dendritic 
cell immunotherapy in HLA risk genotype-positive rheumatoid 
arthritis patients. Sci Transl Med 7(290):290287
 8. Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M 
(2011) Phase I (safety) study of autologous tolerogenic dendritic 
cells in type 1 diabetic patients. Diabetes Care 34(9):2026–2032. 
https ://doi.org/10.2337/dc11-0472
 9. Jauregui-Amezaga A, Cabezon R, Ramirez-Morros A, Espana 
C, Rimola J, Bru C, Pino-Donnay S, Gallego M, Masamunt MC, 
Ordas I, Lozano M, Cid J, Panes J, Benitez-Ribas D, Ricart E 
2873Low‑dose 2‑deoxy glucose stabilises tolerogenic dendritic cells and generates potent in vivo…
1 3
(2015) Intraperitoneal administration of autologous tolerogenic 
dendritic cells for refractory Crohn’s disease: a phase I study. J 
Crohns Colitis 9(12):1071–1078. https ://doi.org/10.1093/ecco-
jcc/jjv14 4
 10. Ahmed MS, Bae YS (2016) Dendritic cell-based immunotherapy 
for rheumatoid arthritis: from bench to bedside. Immune Netw 
16(1):44–51. https ://doi.org/10.4110/in.2016.16.1.44
 11. Domogalla MP, Rostan PV, Raker VK, Steinbrink K (2017) Tol-
erance through education: how tolerogenic dendritic cells shape 
immunity. Front Immunol 8:1764. https ://doi.org/10.3389/fimmu 
.2017.01764 
 12. Florez-Grau G, Zubizarreta I, Cabezon R, Villoslada P, Ben-
itez-Ribas D (2018) Tolerogenic dendritic cells as a promising 
antigen-specific therapy in the treatment of multiple sclerosis 
and neuromyelitis optica from preclinical to clinical trials. Front 
Immunol 9:1169. https ://doi.org/10.3389/fimmu .2018.01169 
 13. Garcia-Gonzalez P, Ubilla-Olguin G, Catalan D, Schinnerling K, 
Aguillon JC (2016) Tolerogenic dendritic cells for reprogram-
ming of lymphocyte responses in autoimmune diseases. Auto-
immun Rev 15(11):1071–1080. https ://doi.org/10.1016/j.autre 
v.2016.07.032
 14. Kim SH, Jung HH, Lee CK (2018) Generation, characteristics 
and clinical trials of ex vivo generated tolerogenic dendritic 
cells. Yonsei Med J 59(7):807–815. https ://doi.org/10.3349/
ymj.2018.59.7.807
 15. Raker VK, Domogalla MP, Steinbrink K (2015) Tolerogenic den-
dritic cells for regulatory T cell induction in man. Front Immunol 
6:569. https ://doi.org/10.3389/fimmu .2015.00569 
 16. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, 
Muramatsu S, Steinman RM (1992) Generation of large num-
bers of dendritic cells from mouse bone marrow cultures supple-
mented with granulocyte/macrophage colony-stimulating factor. 
J Exp Med 176(6):1693–1702
 17. Inaba K, Swiggard WJ, Steinman RM, Romani N, Schuler G, 
Brinster C (2009) Isolation of dendritic cells. Curr Protoc Immu-
nol Chapter 3:3–7
 18. Anderson AE, Swan DJ, Wong OY, Buck M, Eltherington O, 
Harry RA, Patterson AM, Pratt AG, Reynolds G, Doran JP, Kirby 
JA, Isaacs JD, Hilkens CM (2017) Tolerogenic dendritic cells 
generated with dexamethasone and vitamin D3 regulate rheu-
matoid arthritis CD4(+) T cells partly via transforming growth 
factor-beta1. Clin Exp Immunol 187(1):113–123. https ://doi.
org/10.1111/cei.12870 
 19. Ferreira GB, Vanherwegen AS, Eelen G, Gutierrez AC, Van 
Lommel L, Marchal K, Verlinden L, Verstuyf A, Nogueira T, 
Georgiadou M, Schuit F, Eizirik DL, Gysemans C, Carmeliet P, 
Overbergh L, Mathieu C (2015) Vitamin D3 induces tolerance 
in human dendritic cells by activation of intracellular metabolic 
pathways. Cell Rep. https ://doi.org/10.1016/j.celre p.2015.01.013
 20. Funda DP, Golias J, Hudcovic T, Kozakova H, Spisek R, Pal-
ova-Jelinkova L (2018) Antigen Loading (e.g., Glutamic Acid 
Decarboxylase 65) of Tolerogenic DCs (tolDCs) reduces their 
capacity to prevent diabetes in the non-obese diabetes (NOD)-
severe combined immunodeficiency model of adoptive cotransfer 
of diabetes as well as in NOD mice. Front Immunol 9:290
 21. Gordon JR, Ma Y, Churchman L, Gordon SA, Dawicki W (2014) 
Regulatory dendritic cells for immunotherapy in immunologic 
diseases. Front Immunol 5:7. https ://doi.org/10.3389/fimmu 
.2014.00007 
 22. Hashimoto-Hill S, Friesen L, Kim M, Kim CH (2017) Contrac-
tion of intestinal effector T cells by retinoic acid-induced puriner-
gic receptor P2X7. Mucosal Immunol 10(4):912–923. https ://doi.
org/10.1038/mi.2016.109
 23. Mansilla MJ, Selles-Moreno C, Fabregas-Puig S, Amoedo J, 
Navarro-Barriuso J, Teniente-Serra A, Grau-Lopez L, Ramo-
Tello C, Martinez-Caceres EM (2015) Beneficial effect of 
tolerogenic dendritic cells pulsed with MOG autoantigen in 
experimental autoimmune encephalomyelitis. CNS Neurosci 
Ther 21(3):222–230. https ://doi.org/10.1111/cns.12342 
 24. Torres-Aguilar H, Aguilar-Ruiz SR, Gonzalez-Perez G, Munguia 
R, Bajana S, Meraz-Rios MA, Sanchez-Torres C (2010) Tolero-
genic dendritic cells generated with different immunosuppressive 
cytokines induce antigen-specific anergy and regulatory proper-
ties in memory CD4+ T cells. J Immunol 184(4):1765–1775. 
https ://doi.org/10.4049/jimmu nol.09021 33
 25. Raverdeau M, Christofi M, Malara A, Wilk MM, Misiak A, Kuf-
fova L, Yu T, McGinley AM, Quinn SM, Massilamany C, Reddy 
J, Forrester JV, Mills KH (2019) Retinoic acid-induced autoan-
tigen-specific type 1 regulatory T cells suppress autoimmunity. 
EMBO Rep 20:1–4. https ://doi.org/10.15252 /embr.20184 7121
 26. Klaska IP, Muckersie E, Martin-Granados C, Christofi M, For-
rester JV (2017) Lipopolysaccharide-primed heterotolerant den-
dritic cells suppress experimental autoimmune uveoretinitis by 
multiple mechanisms. Immunology 150(3):364–377. https ://doi.
org/10.1111/imm.12691 
 27. Garcia-Gonzalez PA, Schinnerling K, Sepulveda-Gutierrez A, 
Maggi J, Hoyos L, Morales RA, Mehdi AM, Nel HJ, Soto L, 
Pesce B, Molina MC, Cuchacovich M, Larrondo ML, Neira O, 
Catalan DF, Hilkens CM, Thomas R, Verdugo RA, Aguillon JC 
(2016) Treatment with dexamethasone and monophosphoryl 
lipid a removes disease-associated transcriptional signatures 
in monocyte-derived dendritic cells from rheumatoid arthritis 
patients and confers tolerogenic features. Front Immunol 7:458. 
https ://doi.org/10.3389/fimmu .2016.00458 
 28. Link C, Bujupi F, Krammer PH, Weyd H (2020) Annexin-
coated particles induce antigen-specific immunosuppression. 
Autoimmunity 53(2):86–94. https ://doi.org/10.1080/08916 
934.2019.17101 34
 29. Guilliams M, Dutertre CA, Scott CL, McGovern N, Sichien D, 
Chakarov S, Van Gassen S, Chen J, Poidinger M, De Prijck S, 
Tavernier SJ, Low I, Irac SE, Mattar CN, Sumatoh HR, Low 
GH, Chung TJ, Chan DK, Tan KK, Hon TL, Fossum E, Bogen 
B, Choolani M, Chan JK, Larbi A, Luche H, Henri S, Saeys 
Y, Newell EW, Lambrecht BN, Malissen B, Ginhoux F (2016) 
Unsupervised high-dimensional analysis aligns dendritic cells 
across tissues and species. Immunity 45(3):669–684. https ://doi.
org/10.1016/j.immun i.2016.08.015
 30. Helft J, Bottcher J, Chakravarty P, Zelenay S, Huotari J, Sch-
raml BU, Goubau D, Reis e Sousa C, (2015) GM-CSF mouse 
bone marrow cultures comprise a heterogeneous population 
of CD11c(+)MHCII(+) Macrophages and Dendritic Cells. 
Immunity 42(6):1197–1211. https ://doi.org/10.1016/j.immun 
i.2015.05.018
 31. Schlitzer A, McGovern N, Teo P, Zelante T, Atarashi K, Low 
D, Ho AW, See P, Shin A, Wasan PS, Hoeffel G, Malleret B, 
Heiseke A, Chew S, Jardine L, Purvis HA, Hilkens CM, Tam J, 
Poidinger M, Stanley ER, Krug AB, Renia L, Sivasankar B, Ng 
LG, Collin M, Ricciardi-Castagnoli P, Honda K, Haniffa M, Gin-
houx F (2013) IRF4 transcription factor-dependent CD11b+ den-
dritic cells in human and mouse control mucosal IL-17 cytokine 
responses. Immunity 38(5):970–983. https ://doi.org/10.1016/j.
immun i.2013.04.011
 32. Shortman K, Sathe P, Vremec D, Naik S, O’Keeffe M (2013) 
Plasmacytoid dendritic cell development. Adv Immunol 
120:105–126. https ://doi.org/10.1016/B978-0-12-41702 
8-5.00004 -1
 33. Jiang HR, Muckersie E, Robertson M, Xu H, Liversidge J, For-
rester JV (2002) Secretion of interleukin-10 or interleukin-12 by 
LPS-activated dendritic cells is critically dependent on time of 
stimulus relative to initiation of purified DC culture. J Leukoc 
Biol 72(5):978–985
2874 M. Christofi et al.
1 3
 34. Satpathy AT, Brown RA, Gomulia E, Briseno CG, Mumbach 
MR, Pan Z, Murphy KM, Natkunam Y, Chang HY, Kim J (2018) 
Expression of the transcription factor ZBTB46 distinguishes 
human histiocytic disorders of classical dendritic cell origin. 
Mod Pathol 31(9):1479–1486. https ://doi.org/10.1038/s4137 
9-018-0052-4
 35. Satpathy AT, Kc W, Albring JC, Edelson BT, Kretzer NM, Bhat-
tacharya D, Murphy TL, Murphy KM (2012) Zbtb46 expression 
distinguishes classical dendritic cells and their committed pro-
genitors from other immune lineages. J Exp Med 209(6):1135–
1152. https ://doi.org/10.1084/jem.20120 030
 36. Sim WJ, Ahl PJ, Connolly JE (2016) Metabolism is central to 
tolerogenic dendritic cell function. Med Inflamm 2016:2636701. 
https ://doi.org/10.1155/2016/26367 01
 37. Kelly B, O’Neill LA (2015) Metabolic reprogramming in 
macrophages and dendritic cells in innate immunity. Cell Res 
25(7):771–784. https ://doi.org/10.1038/cr.2015.68
 38. Wick AN, Drury DR, Nakada HI, Wolfe JB (1957) Localization 
of the primary metabolic block produced by 2-deoxyglucose. J 
Biol Chem 224(2):963–969
 39. Jantsch J, Chakravortty D, Turza N, Prechtel AT, Buchholz B, 
Gerlach RG, Volke M, Glasner J, Warnecke C, Wiesener MS, 
Eckardt KU, Steinkasserer A, Hensel M, Willam C (2008) 
Hypoxia and hypoxia-inducible factor-1 alpha modulate lipopol-
ysaccharide-induced dendritic cell activation and function. J 
Immunol 180(7):4697–4705
 40. Krawczyk CM, Holowka T, Sun J, Blagih J, Amiel E, DeBerar-
dinis RJ, Cross JR, Jung E, Thompson CB, Jones RG, Pearce EJ 
(2010) Toll-like receptor-induced changes in glycolytic metabo-
lism regulate dendritic cell activation. Blood 115(23):4742–
4749. https ://doi.org/10.1182/blood -2009-10-24954 0
 41. Liu RT, Zhang M, Yang CL, Zhang P, Zhang N, Du T, Ge MR, 
Yue LT, Li XL, Li H, Duan RS (2018) Enhanced glycolysis con-
tributes to the pathogenesis of experimental autoimmune neuri-
tis. J Neuroinflammation 15(1):51. https ://doi.org/10.1186/s1297 
4-018-1095-7
 42. Xu H, Koch P, Chen M, Lau A, Reid DM, Forrester JV (2008) 
A clinical grading system for retinal inflammation in the chronic 
model of experimental autoimmune uveoretinitis using digi-
tal fundus images. Exp Eye Res 87(4):319–326. https ://doi.
org/10.1016/j.exer.2008.06.012
 43. Caspi RR, Roberge FG, Chan CC, Wiggert B, Chader GJ, Rozen-
szajn LA, Lando Z, Nussenblatt RB (1988) A new model of 
autoimmune disease Experimental autoimmune uveoretinitis 
induced in mice with two different retinal antigens. J Immunol 
140(5):1490–1495
 44. Jin D, Sprent J (2018) GM-CSF culture revisited: preparation 
of bulk populations of highly pure dendritic cells from mouse 
bone marrow. J Immunol 201(10):3129–3139. https ://doi.
org/10.4049/jimmu nol.18000 31
 45. Jiang HR, Muckersie E, Robertson M, Forrester JV (2003) 
Antigen-specific inhibition of experimental autoimmune uve-
oretinitis by bone marrow-derived immature dendritic cells. 
Invest Ophthalmol Vis Sci 44(4):1598–1607
 46. Stoop JN, Robinson JH, Hilkens CM (2011) Developing tolero-
genic dendritic cell therapy for rheumatoid arthritis: what can 
we learn from mouse models? Ann Rheum Dis 70(9):1526–
1533. https ://doi.org/10.1136/ard.2011.15165 4
 47. Zhang J, Supakorndej T, Krambs JR, Rao M, Abou-Ezzi G, Ye 
RY, Li S, Trinkaus K, Link DC (2019) Bone marrow dendritic 
cells regulate hematopoietic stem/progenitor cell trafficking. J 
Clin Invest 129(7):2920–2931. https ://doi.org/10.1172/JCI12 
4829
 48. Hilkens CM, Isaacs JD, Thomson AW (2010) Development of 
dendritic cell-based immunotherapy for autoimmunity. Int Rev 
Immunol 29(2):156–183. https ://doi.org/10.3109/08830 18090 
32811 93
 49. O’Neill LA, Pearce EJ (2016) Immunometabolismgoverns den-
dritic cell and macropahge function. J Exp Med 213:15–23
 50. Liu K, Victora GD, Schwickert TA, Guermonprez P, Meredith 
MM, Yao K, Chu FF, Randolph GJ, Rudensky AY, Nussenz-
weig M (2009) In vivo analysis of dendritic cell development 
and homeostasis. Science 324(5925):392–397. https ://doi.
org/10.1126/scien ce.11705 40
 51. Merad M, Sathe P, Helft J, Miller J, Mortha A (2013) The 
dendritic cell lineage: ontogeny and function of dendritic cells 
and their subsets in the steady state and the inflamed setting. 
Annu Rev Immunol 31:563–604. https ://doi.org/10.1146/annur 
ev-immun ol-02071 1-07495 0
 52. Miyagawa F, Gutermuth J, Zhang H, Katz SI (2010) The use 
of mouse models to better understand mechanisms of autoim-
munity and tolerance. J Autoimmun 35(3):192–198. https ://
doi.org/10.1016/j.jaut.2010.06.007
 53. Hobo W, Maas F, Adisty N, de Witte T, Schaap N, van der 
Voort R, Dolstra H (2010) siRNA silencing of PD-L1 and 
PD-L2 on dendritic cells augments expansion and function of 
minor histocompatibility antigen-specific CD8+ T cells. Blood 
116(22):4501–4511. https ://doi.org/10.1182/blood -2010-04-
27873 9
 54. Matlung HL, Szilagyi K, Barclay NA, van den Berg TK (2017) 
The CD47-SIRPalpha signaling axis as an innate immune 
checkpoint in cancer. Immunol Rev 276(1):145–164. https ://
doi.org/10.1111/imr.12527 
 55. Liu Q, Wen W, Tang L, Qin CJ, Lin Y, Zhang HL, Wu H, 
Ashton C, Wu HP, Ding J, Dong W, Yu LX, Yang W, 
Huang DD, Wu MC, Wang HY, Yan HX (2016) Inhibition 
of SIRPalpha in dendritic cells potentiates potent antitumor 
immunity. Oncoimmunology 5(9):e1183850. https ://doi.
org/10.1080/21624 02X.2016.11838 50
 56. Petvises S, Periasamy P, O’Neill HC (2018) MCSF drives 
regulatory DC development in stromal co-cultures support-
ing hematopoiesis. BMC Immunol 19(1):21. https ://doi.
org/10.1186/s1286 5-018-0255-y
 57. Saito Y, Respatika D, Komori S, Washio K, Nishimura T, 
Kotani T, Murata Y, Okazawa H, Ohnishi H, Kaneko Y, Yui 
K, Yasutomo K, Nishigori C, Nojima Y, Matozaki T (2017) 
SIRPalpha(+) dendritic cells regulate homeostasis of fibroblas-
tic reticular cells via TNF receptor ligands in the adult spleen. 
Proc Natl Acad Sci USA 114(47):E10151–E10160. https ://doi.
org/10.1073/pnas.17113 45114 
 58. Washio K, Kotani T, Saito Y, Respatika D, Murata Y, Kaneko 
Y, Okazawa H, Ohnishi H, Fukunaga A, Nishigori C, Matozaki 
T (2015) Dendritic cell SIRPalpha regulates homeostasis of 
dendritic cells in lymphoid organs. Genes Cells 20(6):451–463. 
https ://doi.org/10.1111/gtc.12238 
 59. Dong LW, Kong XN, Yan HX, Yu LX, Chen L, Yang W, Liu Q, 
Huang DD, Wu MC, Wang HY (2008) Signal regulatory protein 
alpha negatively regulates both TLR3 and cytoplasmic pathways 
in type I interferon induction. Mol Immunol 45(11):3025–3035. 
https ://doi.org/10.1016/j.molim m.2008.03.012
 60. Ahmad A, Biersack B, Li Y, Kong D, Bao B, Schobert R, Pad-
hye SB, Sarkar FH (2013) Targeted regulation of PI3K/Akt/
mTOR/NF-κB signaling by indole compounds and their deriva-
tives: mechanistic details and biological implications for cancer 
therapy. Anticancer Agents Med Chem 13(7):1002–1013. https 
://doi.org/10.2174/18715 20611 31399 90078 
 61. Everts B, Pearce EJ (2014) Metabolic control of dendritic cell 
activation and function: recent advances and clinical implica-
tions. Front Immunol 5:203. https ://doi.org/10.3389/fimmu 
.2014.00203 
2875Low‑dose 2‑deoxy glucose stabilises tolerogenic dendritic cells and generates potent in vivo…
1 3
 62. Abboud G, Choi SC, Kanda N, Zeumer-Spataro L, Roopenian 
DC, Morel L (2018) Inhibition of glycolysis reduces disease 
severity in an autoimmune model of rheumatoid arthritis. Front 
Immunol 9:1973. https ://doi.org/10.3389/fimmu .2018.01973 
 63. Okano T, Saegusa J, Nishimura K, Takahashi S, Sendo S, Ueda 
Y, Morinobu A (2017) 3-bromopyruvate ameliorate autoimmune 
arthritis by modulating Th17/Treg cell differentiation and sup-
pressing dendritic cell activation. Sci Rep 7:42412. https ://doi.
org/10.1038/srep4 2412
 64. Lau AW, Biester S, Cornall RJ, Forrester JV (2008) Lipopol-
ysaccharide-activated IL-10-secreting dendritic cells suppress 
experimental autoimmune uveoretinitis by MHCII-dependent 
activation of CD62L-expressing regulatory T cells. J Immunol 
180(6):3889–3899
 65. Siepmann K, Biester S, Plskova J, Muckersie E, Duncan L, For-
rester JV (2007) CD4+CD25+ T regulatory cells induced by 
LPS-activated bone marrow dendritic cells suppress experimen-
tal autoimmune uveoretinitis in vivo. Graefes Arch Clin Exp 
Ophthalmol 245(2):221–229. https ://doi.org/10.1007/s0041 
7-006-0356-9
 66. Pearce EJ, Everts B (2015) Dendritic cell metabolism. Nat Rev 
Immunol 15(1):18–29. https ://doi.org/10.1038/nri37 71
 67. Sun Y, Oravecz-Wilson K, Bridges S, McEachin R, Wu J, Kim 
SH, Taylor A, Zajac C, Fujiwara H, Peltier DC, Saunders T, 
Reddy P (2019) miR-142 controls metabolic reprogramming that 
regulates dendritic cell activation. J Clin Investig 129(5):2029–
2042. https ://doi.org/10.1172/JCI12 3839
 68. Everts B, Amiel E, Huang SC, Smith AM, Chang CH, Lam WY, 
Redmann V, Freitas TC, Blagih J, van der Windt GJ, Artyomov 
MN, Jones RG, Pearce EL, Pearce EJ (2014) TLR-driven early 
glycolytic reprogramming via the kinases TBK1-IKKvarepsilon 
supports the anabolic demands of dendritic cell activation. Nat 
Immunol 15(4):323–332. https ://doi.org/10.1038/ni.2833
 69. Malinarich F, Duan K, Hamid RA, Bijin A, Lin WX, Poidinger 
M, Fairhurst AM, Connolly JE (2015) High mitochondrial res-
piration and glycolytic capacity represent a metabolic phenotype 
of human tolerogenic dendritic cells. J Immunol 194(11):5174–
5186. https ://doi.org/10.4049/jimmu nol.13033 16
 70. Morris G, Berk M, Carvalho A, Caso JR, Sanz Y, Walder K, 
Maes M (2017) The role of the microbial metabolites including 
tryptophan catabolites and short chain fatty acids in the patho-
physiology of immune-inflammatory and neuroimmune disease. 
Mol Neurobiol 54(6):4432–4451. https ://doi.org/10.1007/s1203 
5-016-0004-2
 71. Vanherwegen AS, Gysemans C, Overbergh L (2015) Den-
dritic cell metabolism: immunity and tolerance. Oncotarget 
6(33):34039–34040. https ://doi.org/10.18632 /oncot arget .5865
 72. Thwe PM, Pelgrom L, Cooper R, Beauchamp S, Reisz JA, 
D’Alessandro A, Everts B, Amiel E (2017) Cell-Intrinsic gly-
cogen metabolism supports early glycolytic reprogramming 
required for dendritic cell immune responses. Cell Metab 
26(3):558–567
 73. Ryan DG, O’Neill LAJ (2017) Krebs cycle rewired for mac-
rophage and dendritic cell effector functions. FEBS Lett 
591(19):2992–3006. https ://doi.org/10.1002/1873-3468.12744 
 74. Iberg CA, Hawiger D (2020) Natural and induced tolerogenic 
dendritic cells. J Immunol 204(4):733. https ://doi.org/10.4049/
jimmu nol.19011 21
 75. Ochando J, Fayad ZA, Madsen JC, Netea MG, Mulder WJM 
(2020) Trained immunity in organ transplantation. Am J Trans 
20(1):10–18. https ://doi.org/10.1111/ajt.15620 
 76. Stallone G, Infante B, Di Lorenzo A, Rascio F, Zaza G, Gran-
daliano G (2016) mTOR inhibitors effects on regulatory T 
cells and on dendritic cells. J Trans Med 14(1):152. https ://doi.
org/10.1186/s1296 7-016-0916-7
 77. Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, 
Nohara K, Fujii-Kuriyama Y, Kishimoto T (2010) Aryl hydro-
carbon receptor negatively regulates dendritic cell immunogenic-
ity via a kynurenine-dependent mechanism. Proc Natl Acad Sci 
USA 107(46):19961–19966. https ://doi.org/10.1073/pnas.10144 
65107 
 78. Salazar F, Awuah D, Negm OH, Shakib F, Ghaemmaghami AM 
(2017) The role of indoleamine 2,3-dioxygenase-aryl hydrocar-
bon receptor pathway in the TLR4-induced tolerogenic pheno-
type in human DCs. Sci Rep 7:43337. https ://doi.org/10.1038/
srep4 3337
 79. Rayner F, Isaacs JD (2018) Therapeutic tolerance in autoimmune 
disease. Semin Arthritis Rheum. https ://doi.org/10.1016/j.semar 
thrit .2018.09.008
 80. Takenaka MC, Quintana FJ (2017) Tolerogenic dendritic 
cells. Seminars in Immunopathol 39(2):113–120. https ://doi.
org/10.1007/s0028 1-016-0587-8
 81. Lord P, Spiering R, Aguillon JC, Anderson AE, Appel S, Ben-
itez-Ribas D, Ten Brinke A, Broere F, Cools N, Cuturi MC, 
Diboll J, Geissler EK, Giannoukakis N, Gregori S, van Ham 
SM, Lattimer S, Marshall L, Harry RA, Hutchinson JA, Isaacs 
JD, Joosten I, van Kooten C, Diaz L, de Cerio A, Nikolic T, Oral 
HB, Sofronic-Milosavljevic L, Ritter T, Riquelme P, Thomson 
AW, Trucco M, Vives-Pi M, Martinez-Caceres EM, Hilkens 
CMU (2016) Minimum information about tolerogenic antigen-
presenting cells (MITAP): a first step towards reproducibility and 
standardisation of cellular therapies. PeerJ 4:e2300. https ://doi.
org/10.7717/peerj .2300
 82. Martin E, Capini C, Duggan E, Lutzky VP, Stumbles P, Pettit 
AR, O’Sullivan B, Thomas R (2007) Antigen-specific sup-
pression of established arthritis in mice by dendritic cells defi-
cient in NF-κB. Arthritis Rheum 56(7):2255–2266. https ://doi.
org/10.1002/art.22655 
 83. Azukizawa H, Dohler A, Kanazawa N, Nayak A, Lipp M, Malis-
sen B, Autenrieth I, Katayama I, Riemann M, Weih F, Berber-
ich-Siebelt F, Lutz MB (2011) Steady state migratory RelB+ 
langerin+ dermal dendritic cells mediate peripheral induction of 
antigen-specific CD4+ CD25+ Foxp3+ regulatory T cells. Eur 
J Immunol 41(5):1420–1434. https ://doi.org/10.1002/eji.20104 
0930
 84. Sage PT, Schildberg FA, Sobel RA, Kuchroo VK, Freeman GJ, 
Sharpe AH (2018) Dendritic cell PD-L1 limits autoimmunity 
and follicular T cell differentiation and function. J Immunol 
200(8):2592. https ://doi.org/10.4049/jimmu nol.17012 31
 85. Barclay AN, Brown MH (2006) The SIRP family of receptors 
and immune regulation. Nat Rev Immunol 6(6):457–464. https 
://doi.org/10.1038/nri18 59
 86. Fortin G, Raymond M, Van VQ, Rubio M, Gautier P, Sarfati M, 
Franchimont D (2009) A role for CD47 in the development of 
experimental colitis mediated by SIRPalpha+CD103- dendritic 
cells. J Exp Med 206(9):1995–2011. https ://doi.org/10.1084/
jem.20082 805
 87. Dugas V, Beauchamp C, Chabot-Roy G, Hillhouse EE, Les-
age S (2010) Implication of the CD47 pathway in autoimmune 
diabetes. J Autoimmun 35(1):23–32. https ://doi.org/10.1016/j.
jaut.2010.01.002
 88. Barclay AN, Van den Berg TK (2014) The interaction between 
signal regulatory protein alpha (SIRPalpha) and CD47: structure, 
function, and therapeutic target. Annu Rev Immunol 32:25–50. 
https ://doi.org/10.1146/annur ev-immun ol-03271 3-12014 2
 89. Baba T, Nakamoto Y, Mukaida N (2009) Crucial contribution 
of thymic Sirp alpha+ conventional dendritic cells to central 
tolerance against blood-borne antigens in a CCR2-dependent 
manner. J Immunol 183(5):3053–3063. https ://doi.org/10.4049/
jimmu nol.09004 38
2876 M. Christofi et al.
1 3
 90. Granot T, Senda T, Carpenter DJ, Matsuoka N, Weiner J, Gor-
don CL, Miron M, Kumar BV, Griesemer A, Ho SH, Lerner H, 
Thome JJ, Connors T, Reizis B, Farber DL (2017) Dendritic 
cells display subset and tissue-specific maturation dynamics over 
human life. Immunity 46(3):504–515. https ://doi.org/10.1016/j.
immun i.2017.02.019
 91. Johansen ML, Brown EJ (2007) Dual regulation of SIRPal-
pha phosphorylation by integrins and CD47. J Biol Chem 
282(33):24219–24230. https ://doi.org/10.1074/jbc.M7015 65200 
 92. Aksoy E, Saveanu L, Manoury B (2018) The isoform selec-
tive roles of PI3Ks in dendritic cell biology and function. Front 
Immunol 9:2574. https ://doi.org/10.3389/fimmu .2018.02574 
 93. Miraghazadeh B, Cook MC (2018) Nuclear Factor-kappaB in 
autoimmunity: man and mouse. Front Immunol 9:613. https ://
doi.org/10.3389/fimmu .2018.00613 
 94. Spoden GA, Rostek U, Lechner S, Mitterberger M, Mazurek S, 
Zwerschke WJE (2009) Pyruvate kinase isoenzyme M2 is a gly-
colytic sensor differentially regulating cell proliferation cell size 
and apoptotic cell death dependent on glucose supply. Exp Cell 
Res 315(16):2765–2774
 95. Wang S, Zhang Y, Cai Q, Ma M, Jin LY, Weng M, Zhou D, Tang 
Z, Wang JD (2019) Circular RNA FOXP1 promotes tumor pro-
gression and Warburg effect in gallbladder cancer by regulating 
PKLR expression. Mol Cancer 18(1):1–15
 96. Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, 
Kumar V, Giamarellos-Bourboulis EJ, Martens JH, Rao NA, 
Aghajanirefah A, Manjeri GR, Li Y, Ifrim DC, Arts RJ, van der 
Veer BM, Deen PM, Logie C, O’Neill LA, Willems P, van de 
Veerdonk FL, van der Meer JW, Ng A, Joosten LA, Wijmenga C, 
Stunnenberg HG, Xavier RJ, Netea MG (2014) mTOR- and HIF-
1alpha-mediated aerobic glycolysis as metabolic basis for trained 
immunity. Science 345(6204):1250684. https ://doi.org/10.1126/
scien ce.12506 84
 97. Palsson-McDermott EM, Dyck L, Zaslona Z, Menon D, 
McGettrick AF, Mills KHG, O’Neill LA (2017) Pyruvate Kinase 
M2 Is required for the expression of the immune checkpoint 
PD-L1 in immune cells and tumors. Front Immunol 8:1300. https 
://doi.org/10.3389/fimmu .2017.01300 
 98. Angiari S, Runtsch MC, Sutton CE, Palsson-McDermott EM, 
Kelly B, Rana N, Kane H, Papadopoulou G, Pearce EL, Mills 
KHG, O’Neill LAJ (2020) Pharmacological activation of pyru-
vate kinase M2 Inhibits CD4+ T cell pathogenicity and sup-
presses autoimmunity. Cell Metab 31(2):391-405.e398. https ://
doi.org/10.1016/j.cmet.2019.10.015
 99. Tee SS, Park JM, Hurd RE, Brimacombe KR, Boxer MB, Mas-
soud TF, Rutt BK, Spielman DMJO (2017) PKM2 activation 
sensitizes cancer cells to growth inhibition by 2-deoxy-d-glucose. 
Oncotarget 8(53):90959
 100. García-González PA, Maggi J, Schinnerling K, Sepúlveda-Gutié-
rrez A, Soto L, Neira O, Mehdi AM, Nel HJ, Pesce B (2019) 
Regulation of tolerogenic features on dexamethasone-modu-
lated MPLA-activated dendritic cells by MYC. Front Immunol 
10:1171
 101. Phillips BE, Garciafigueroa Y, Engman C, Trucco M, Giannouk-
akis N (2019) Tolerogenic Dendritic Cells and T-regulatory cells 
at the clinical trials crossroad for the treatment of autoimmune 
disease; emphasis on type 1 diabetes therapy. Front Immunol 
10:148
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
